UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


	☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2022~~2023


	☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______to _______

Commission File Number: 001-35737

NORTHWEST BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	94-3306718
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

4800 Montgomery Lane, Suite 800, Bethesda, MD 20814

(Address of principal executive offices) (Zip Code)

(240) 497-9024

(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.001 per share	NWBO	OTCQB

As of ~~November 8, 2022,~~August 7, 2023, the total number of shares of common stock, par value $0.001 per share, outstanding was ~~1,052,853,970.~~1,121,070,972.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

FORM 10-Q

TABLE OF CONTENTS


PART I - FINANCIAL INFORMATION		3

Item 1.	Condensed Consolidated Interim Financial Statements (Unaudited)

	Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2022~~2023 and December 31, ~~2021~~2022	3

	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022	4

	Condensed Consolidated Statements of Stockholders’ Deficit for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022	5

	Condensed Consolidated Statements of Cash Flows for the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022	7

	Notes to Condensed Consolidated Financial Statements	9

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2426

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2831

Item 4.	Controls and Procedures	2932

PART II - OTHER INFORMATION		3033

Item 1.	Legal Proceedings	3033

Item 1A.	Risk Factors	3033

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3033

Item 3.	Defaults Upon Senior Securities	3033

Item 4.	Mine Safety Disclosures	3033

Item 5.	Other Information	3033

Item 6.	Exhibits	3134

SIGNATURES		3235

Table of Contents

PART I - FINANCIAL INFORMATION

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

September 30,

December 31,

2022

2021

(Unaudited)

ASSETS



Current assets:




Cash and cash equivalents

$
9,425

$
15,169
Prepaid expenses and other current assets

2,339

2,121
Total current assets

11,764

17,290

Non-current assets:

Property, plant and equipment, net

13,126

15,027
Right-of-use asset, net

3,951

4,889
Indefinite-lived intangible asset

1,292

1,292
Goodwill

626

626
Other assets

339

1,036
Total non-current assets

19,334

22,870

TOTAL ASSETS

$
31,098

$
40,160

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current liabilities:

Accounts payable and accrued expenses

$
8,237

$
6,976
Accounts payable and accrued expenses to related parties and affiliates

5,728

3,971
Convertible notes, net

135

135
Notes payable, net

20,032

7,104
Contingent payable derivative liability

8,012

8,232
Warrant liability

73,650

106,784
Lease liabilities

334

317
Shares payable

—

250
Total current liabilities

116,128

133,769

Non-current liabilities:

Notes payable, net of current portion, net

5,942

25,156
Lease liabilities, net of current portion

4,132

5,226
Total non-current liabilities

10,074

30,382

Total liabilities

126,202

164,151

COMMITMENTS AND CONTINGENCIES (Note 11)

MEZZANINE EQUITY

Series C Convertible Preferred Stock, 10,000,000 shares designated; 885,155 and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively; aggregate liquidation preference of $13.2 million

13,746

—

Stockholders’ deficit:

Preferred stock ($0.001 par value); 100,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively

—

—
Common stock ($0.001 par value); 1,200,000,000 shares authorized; 1,051.3 million and 948.4 million shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

1,051

948
Additional paid-in capital

1,152,689

1,066,873
Stock subscription receivable

(79)

(79)
Accumulated deficit

(1,268,824)

(1,192,090)
Accumulated other comprehensive income

6,313

357
Total stockholders’ deficit

(108,850)

(123,991)

TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT

$
31,098

$
40,160


	June 30,		December 31,
	2023		2022
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	1,424	$	6,965
Prepaid expenses and other current assets		3,218		2,460
Total current assets		4,642		9,425

Non-current assets:
Property, plant and equipment, net		17,286		13,418
Construction in progress		—		2,028
Right-of-use asset, net		4,231		4,189
Indefinite-lived intangible asset		1,292		1,292
Goodwill		626		626
Other assets		361		345
Total non-current assets		23,796		21,898

TOTAL ASSETS	$	28,438	$	31,323

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	12,107	$	10,687
Accounts payable and accrued expenses to related parties and affiliates		6,551		6,955
Convertible notes, net		1,858		135
Notes payable, net		8,403		15,403
Contingent payable derivative liability		8,706		8,668
Warrant liability		1,083		80,559
Investor advances		609		2,566
Share liability		223		678
Lease liabilities		385		354
Total current liabilities		39,925		126,005

Non-current liabilities:
Notes payable, net of current portion, net		15,743		5,991
Lease liabilities, net of current portion		4,369		4,370
Contingent payment obligation		4,050		—
Total non-current liabilities		24,162		10,361

Total liabilities		64,087		136,366

COMMITMENTS AND CONTINGENCIES (Note 12)

Mezzanine equity:
Series C Convertible Preferred Stock, 10,000,000 shares designated; 1.5 million and 1.4 million shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $23.7 million		25,385		23,060

Stockholders’ deficit:
Preferred stock ($0.001 par value); 100,000,000 shares authorized as of June 30, 2023 and December 31, 2022, respectively		—		—
Common stock ($0.001 par value); 1,700,000,000 shares authorized; 1,115.2 million and 1,068.4 million shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively		1,115		1,068
Additional paid-in capital		1,258,259		1,164,885
Stock subscription receivable		(79)		(79)
Accumulated deficit		(1,322,222)		(1,297,122)
Accumulated other comprehensive income		1,893		3,145
Total stockholders’ deficit		(61,034)		(128,103)

TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT	$	28,438	$	31,323

The accompanying notes are an integral part of these unaudited condensed consolidated financial ~~statements~~statements.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amounts)

(Unaudited)

For the three months ended

For the nine months ended

September 30,

September 30,


2022

2021

2022

2021
Revenues:

Research and other

$
206

$
350

$
1,086

$
1,005
Total revenues

206

350

1,086

1,005
Operating costs and expenses:

Research and development

7,694

3,748

26,159

16,122
General and administrative

8,130

6,651

23,930

26,909
Total operating costs and expenses

15,824

10,399

50,089

43,031
Loss from operations

(15,618)

(10,049)

(49,003)

(42,026)
Other (expense) income:

Change in fair value of derivative liabilities

(12,169)

58,473

(15,883)

93,536
Loss from extinguishment of debt

(456)

—

(156)

(144)
Interest expense

(1,512)

(1,604)

(4,847)

(3,858)
Inducement expense

—

(314)

—

(314)
Foreign currency transaction loss

(3,097)

(987)

(6,845)

(1,388)
Total other (loss) income

(17,234)

55,568

(27,731)

87,832
Net (loss) income

$
(32,852)

$
45,519

$
(76,734)

$
45,806

Other comprehensive (loss) income

Foreign currency translation adjustment

2,773

836

5,956

1,186
Total comprehensive (loss) income

$
(30,079)

$
46,355

$
(70,778)

$
46,992

Net (loss) earnings per share applicable to common stockholders

Basic

$
(0.03)

$
0.05

$
(0.08)

$
0.05
Diluted

$
(0.03)

$
(0.01)

$
(0.08)

$
(0.04)

Weighted average shares used in computing basic (loss) earnings per share

1,040,982

875,963

1,001,703

854,276
Weighted average shares used in computing diluted (loss) earnings per share

1,040,982

1,135,762

1,001,703

1,099,598


	For the three months ended				For the six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Revenues:
Research and other	$	201	$	477	$	1,081	$	880
Total revenues		201		477		1,081		880
Operating costs and expenses:
Research and development		6,214		13,645		13,075		18,465
General and administrative		7,564		7,931		14,547		15,800
Total operating costs and expenses		13,778		21,576		27,622		34,265
Loss from operations		(13,577)		(21,099)		(26,541)		(33,385)
Other income (expense):
Change in fair value of derivative liabilities		107		(4,254)		3,987		(3,714)
Change in fair value of share liabilities		99		—		47		—
(Loss) gain from extinguishment of debt		(472)		(110)		(1,880)		300
Interest expense		(1,302)		(1,432)		(2,329)		(3,335)
Foreign currency transaction gain (loss)		697		(2,773)		1,616		(3,748)
Total other income (loss)		(871)		(8,569)		1,441		(10,497)
Net loss		(14,448)		(29,668)		(25,100)		(43,882)
Deemed dividend related to warrant modification		(519)		—		(914)		—
Net loss attributable to common stockholders	$	(14,967)	$	(29,668)	$	(26,014)	$	(43,882)

Other comprehensive income (loss)
Foreign currency translation adjustment		(502)		2,375		(1,252)		3,183
Total comprehensive loss	$	(15,469)	$	(27,293)	$	(27,266)	$	(40,699)

Net loss per share applicable to common stockholders
Basic	$	(0.01)	$	(0.01)	$	(0.02)	$	0.21
Diluted	$	(0.01)	$	(0.01)	$	(0.02)	$	(0.06)

Weighted average shares used in computing basic loss per share		1,108,420		1,003,976		1,091,754		981,737
Weighted average shares used in computing diluted loss per share		1,108,420		1,003,976		1,091,754		981,737

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(in thousands)

(Unaudited)


	For the Three Months Ended September 30, 2022																For the Three Months Ended June 30, 2023
													Accumulated				Mezzanine equity												Accumulated
	Series C Covertible						Additional						Other		Total		Series C Convertible						Additional						Other		Total
	Preferred Stock			Common Stock			Paid-in		Subscription		Accumulated		Comprehensive		Stockholders’		Preferred Stock			Common Stock			Paid-in		Subscription		Accumulated		Comprehensive		Stockholders'
	Shares	Amount		Shares	Par value		Capital		Receivable		Deficit		Income		Deficit		Shares	Amount		Shares	Par value		Capital		Receivable		Deficit		Income		Deficit
Balances at July 1, 2022	—	$	—	1,034,475	$	1,034	$	1,139,811	$	(79)	$	(1,235,972)	$	3,540	$	(91,666)
Balances at April 1, 2023																	1,416	$	23,752	1,083,084	$	1,083	$	1,248,397	$	(79)	$	(1,307,774)	$	2,395	$	(55,978)
Issuance of Series C convertible preferred stock for cash	704		10,904	—		—		—		—		—		—		—	176		2,371	—		—		—		—		—		—		—
Issuance of Series C convertible preferred stock in lieu of debt redemption	126		1,978	—		—		—		—		—		—		—	13		207	—		—		—		—		—		—		—
Issuance of Series C convertible preferred stock by common stock warrant exercise	55		329	—		—		—		—		—		—		—
Series C convertible preferred stock conversion																	(59)		(945)	1,484		2		943		—		—		—		945
Warrants exercised for cash	—		—	1,926		2		428		—		—		—		430	—		—	11,553		11		2,510		—		—		—		2,521
Reclassification of warrant liabilities related to warrants exercised for cash	—		535	—		—		2,402		—		—		—		2,402
Cashless warrants and stock options exercised	—		—	5,321		5		(5)		—		—		—		—
Reclassification of warrant liabilities related to cashless warrants exercise	—		—	—		—		1,421		—		—		—		1,421
Cashless warrants and stock options exercise																	—		—	9,169		9		(9)		—		—		—		—
Issuance of common stock for conversion of debt and accrued interest	—		—	6,892		7		5,274		—		—		—		5,281	—		—	6,893		7		3,941		—		—		—		3,948

Stock-based compensation	—		—	2,636		3		3,358		—		—		—		3,361	—		—	3,000		3		187		—		—		—		190
Fractional shares adjustment	—		—	10		—		—		—		—		—		—
Reclass issued milestone shares from liability to equity																	—		—	—		—		2,130		—		—		—		2,130
Net loss	—		—	—		—		—		—		(32,852)		—		(32,852)	—		—	—		—		—		—		(14,448)		—		(14,448)
Warrants modification																	—		—	—		—		679		—		—		—		679
Deemed dividend related to warrants modification																	—		—	—		—		(519)		—		—		—		(519)
Cumulative translation adjustment	—		—	—		—		—		—		—		2,773		2,773	—		—	—		—		—		—		—		(502)		(502)
Balances at September 30, 2022	885	$	13,746	1,051,260	$	1,051	$	1,152,689	$	(79)	$	(1,268,824)	$	6,313	$	(108,850)
Balances at June 30, 2023																	1,546	$	25,385	1,115,183	$	1,115	$	1,258,259	$	(79)	$	(1,322,222)	$	1,893	$	(61,034)


	For the Three Months Ended September 30, 2021													For the Three Months Ended June 30, 2022
										Accumulated													Accumulated
				Additional						Other		Total					Additional						Other		Total
	Common Stock			Paid-in		Subscription		Accumulated		Comprehensive		Stockholders’		Common Stock			Paid-in		Subscription		Accumulated		Comprehensive		Stockholders'
	Shares	Par value		Capital		Receivable		Deficit		Income (Loss)		Deficit		Shares	Par value		Capital		Receivable		Deficit		Income		Deficit
Balance at July 1, 2021	857,230	$	857	$	1,021,107	$	(79)	$	(1,370,929)	$	(798)	$	(349,842)
Balances at April 1, 2022														969,697	$	970	$	1,083,723	$	(79)	$	(1,206,304)	$	1,165	$	(120,525)
Issuance of common stock for cash														8,584		8		6,317		—		—		—		6,325
Warrants exercised for cash	34,142		34		8,001		—		—		—		8,035	23,747		24		5,347		—		—		—		5,371
Reclassification of warrant liabilities related to warrants exercised for cash	—		—		23,018		—		—		—		23,018	—		—		11,973		—		—		—		11,973
Cashless warrants and stock options exercise	488		1		(1)		—		—		—		—	28,877		29		(29)		—		—		—		—
Reclassification of warrant liabilities related to cashless warrants exercise	—		—		4		—		—		—		4	—		—		25,375		—		—		—		25,375
Issuance of common stock conversion of debt and accrued interest														2,070		2		1,343		—		—		—		1,345
Stock-based compensation	—		—		1,263		—		—		—		1,263	1,500		1		5,762		—		—		—		5,763
Reclassification of warrant liabilities based on authorized shares	—		—		(30,566)		—		—		—		(30,566)
Net income	—		—		—		—		45,519		—		45,519
Net loss														—		—		—		—		(29,668)		—		(29,668)
Cumulative translation adjustment	—		—		—		—		—		836		836	—		—		—		—		—		2,375		2,375
Balance at September 30, 2021	891,860	$	892	$	1,022,826	$	(79)	$	(1,325,410)	$	38	$	(301,733)
Balances at June 30, 2022														1,034,475	$	1,034	$	1,139,811	$	(79)	$	(1,235,972)	$	3,540	$	(91,666)

The accompanying notes are an integral part of these unaudited condensed consolidated financial ~~statements~~statements.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(in thousands)

(Unaudited)


	For the Nine Months Ended September 30, 2022																For the Six Months Ended June 30, 2023
													Accumulated				Mezzanine equity												Accumulated
	Series C Covertible						Additional						Other		Total		Series C Convertible						Additional						Other		Total
	Preferred Stock			Common Stock			Paid-in		Subscription		Accumulated		Comprehensive		Stockholders’		Preferred Stock			Common Stock			Paid-in		Subscription		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Par value		Capital		Receivable		Deficit		Income		Deficit		Shares	Amount		Shares	Par value		Capital		Receivable		Deficit		Income		Deficit
Balances at January 1, 2022	—	$	—	948,445	$	948	$	1,066,873	$	(79)	$	(1,192,090)	$	357	$	(123,991)
Balances at January 1, 2023																	1,415	$	23,060	1,068,394	$	1,068	$	1,164,885	$	(79)	$	(1,297,122)	$	3,145	$	(128,103)
Issuance of Series C convertible preferred stock for cash	704		10,904	—		—		—		—		—		—		—	324		4,756	—		—		—		—		—		—		—
Issuance of Series C convertible preferred stock in lieu of debt redemption	126		1,978	—		—		—		—		—		—		—	56		1,013	—		—		—		—		—		—		—
Issuance of Series C convertible preferred stock by common stock warrant exercise	55		329	—		—		—		—		—		—		—
Issuance of common stock for cash	—		—	13,147		13		9,676		—		—		—		9,689
Series C convertible preferred stock conversion																	(257)		(3,562)	6,430		7		3,555		—		—		—		3,562
Warrants exercised for cash	—		—	40,929		41		9,945		—		—		—		9,986	—		—	12,320		12		2,757		—		—		—		2,769
Reclassification of warrant liabilities related to warrants exercised for cash	—		535	—		—		22,090		—		—		—		22,090
Cashless warrants and stock options exercise	—		—	34,224		34		(34)		—		—		—		—	—		—	9,879		10		(10)		—		—		—		—
Reclassification of warrant liabilities related to cashless warrants exercise	—		—	—		—		26,800		—		—		—		26,800
Reclassification of warrant liabilities to stockholders’ deficit																	—		—	—		—		76,258		—		—		—		76,258
Issuance of common stock for conversion of debt and accrued interest	—		—	10,374		11		7,602		—		—		—		7,613	—		—	15,160		15		9,549		—		—		—		9,564
Stock-based compensation	—		—	4,141		4		9,737		—		—		—		9,741	8		118	3,000		3		1,105		—		—		—		1,108
Net loss	—		—	—		—		—		—		(76,734)		—		(76,734)	—		—	—		—		—		—		(25,100)		—		(25,100)
Warrants modification																	—		—	—		—		1,074		—		—		—		1,074
Deemed dividend related to warrants modification																	—		—	—		—		(914)		—		—		—		(914)
Cumulative translation adjustment	—		—	—		—		—		—		—		5,956		5,956	—		—	—		—		—		—		—		(1,252)		(1,252)
Balances at September 30, 2022	885	$	13,746	1,051,260	$	1,051	$	1,152,689	$	(79)	$	(1,268,824)	$	6,313	$	(108,850)
Balances at June 30, 2023																	1,546	$	25,385	1,115,183	$	1,115	$	1,258,259	$	(79)	$	(1,322,222)	$	1,893	$	(61,034)


	For the Nine Months Ended September 30, 2021													For the Six Months Ended June 30, 2022
										Accumulated													Accumulated
				Additional						Other		Total					Additional						Other		Total
	Common Stock			Paid-in		Subscription		Accumulated		Comprehensive		Stockholders’		Common Stock			Paid-in		Subscription		Accumulated		Comprehensive		Stockholders’
	Shares	Par value		Capital		Receivable		Deficit		Income (Loss)		Deficit		Shares	Par value		Capital		Receivable		Deficit		Income		Deficit
Balance at January 1, 2021	829,631	$	830	$	1,008,665	$	(79)	$	(1,371,216)	$	(1,148)	$	(362,948)
Balances at January 1, 2022														948,445	$	948	$	1,066,873	$	(79)	$	(1,192,090)	$	357	$	(123,991)
Issuance of common stock for cash	69		—		16		—		—		—		16	13,137		13		9,676		—		—		—		9,689
Issuance of common stock and warrants for conversion of debt and accrued interest	5,145		5		7,495		—		—		—		7,500
Warrants and stock options exercised for cash	50,340		50		12,058		—		—		—		12,108
Warrants exercised for cash														39,003		39		9,517		—		—		—		9,556
Reclassification of warrant liabilities related to warrants exercised for cash	—		—		34,412		—		—		—		34,412	—		—		19,688		—		—		—		19,688
Cashless warrants and stock options exercise	6,627		7		(7)		—		—		—		—	28,903		29		(29)		—		—		—		—
Reclassification of warrant liabilities related to cashless warrants exercise	—		—		1,596		—		—		—		1,596	—		—		25,379		—		—		—		25,379
Issuance of common stock conversion of debt and accrued interest														3,482		4		2,328		—		—		—		2,332
Stock-based compensation	48		—		14,705		—		—		—		14,705	1,505		1		6,379		—		—		—		6,380
Reclassification of warrant liabilities based on authorized shares	—		—		(56,114)		—		—		—		(56,114)
Net income	—		—		—		—		45,806		—		45,806
Net loss														—		—		—		—		(43,882)		—		(43,882)
Cumulative translation adjustment	—		—		—		—		—		1,186		1,186	—		—		—		—		—		3,183		3,183
Balance at September 30, 2021	891,860	$	892	$	1,022,826	$	(79)	$	(1,325,410)	$	38	$	(301,733)
Balances at June 30, 2022														1,034,475	$	1,034	$	1,139,811	$	(79)	$	(1,235,972)	$	3,540	$	(91,666)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

For the nine months ended

September 30,

2022

2021
Cash Flows from Operating Activities:

Net (loss) income

$
(76,734)

$
45,806
Reconciliation of net (loss) income to net cash used in operating activities:

Depreciation and amortization

934

240
Amortization of debt discount

2,111

1,721
Change in fair value of derivatives

15,883

(93,536)
Loss from extinguishment of debt

156

144
Inducement expense

—

314
Amortization of operating lease right-of-use asset

184

206
Stock-based compensation

9,741

14,632
Subtotal of non-cash charges

29,009

(76,279)
Changes in operating assets and liabilities:

Prepaid expenses and other current assets

(310)

3,113
Other non-current assets

633

(198)
Accounts payable and accrued expenses

1,251

2,351
Related party accounts payable and accrued expenses

2,127

(1,845)
Lease liabilities

98

(1)
Net cash used in operating activities

(43,926)

(27,053)
Cash Flows from Investing Activities:

Purchase of equipment and construction in progress

(742)

(4,462)
Net cash used in investing activities

(742)

(4,462)
Cash Flows from Financing Activities:

Proceeds from issuance of Series C convertible preferred stock

10,904

—
Proceeds from issuance of Series C convertible preferred stock by common stock warrant exercise, net of debt redemption

52

—
Proceeds from issuance of common stock, net

9,465

16
Proceeds from exercise of warrants and stock options

9,986

12,108
Proceeds from issuance of notes payable, net

5,600

13,574
Investor advances

—

767
Repayment of notes payable

(5,390)

(2,003)
Net cash provided by financing activities

30,617

24,462
Effect of exchange rate changes on cash and cash equivalents

8,307

906
Net decrease in cash and cash equivalents

(5,744)

(6,147)

Cash and cash equivalents, beginning of the period

15,169

9,983
Cash and cash equivalents, end of the period

$
9,425

$
3,836

Supplemental disclosure of cash flow information

Interest payments on notes payable

$
(912)

$
(506)


	For the six months ended
	June 30,
	2023		2022
Cash Flows from Operating Activities:
Net loss	$	(25,100)	$	(43,882)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization		685		624
Amortization of debt discount		1,276		1,509
Change in fair value of derivatives		(3,987)		3,714
Change in fair value of share liability		(47)		—
Loss (gain) from extinguishment of debt		1,880		(300)
Amortization of operating lease right-of-use asset		138		121
Stock-based compensation for services		1,211		6,380
Subtotal of non-cash charges		1,156		12,048
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(681)		(286)
Other non-current assets		(14)		660
Accounts payable and accrued expenses		2,206		1,533
Related party accounts payable and accrued expenses		(404)		2,056
Lease liabilities		77		63
Net cash used in operating activities		(22,760)		(27,808)
Cash Flows from Investing Activities:
Purchase of equipment and construction in progress		(2,582)		(466)
Net cash used in investing activities		(2,582)		(466)
Cash Flows from Financing Activities:
Proceeds from issuance of Series C convertible preferred stock		4,756		—
Proceeds from issuance of common stock		—		9,465
Proceeds from exercise of warrants		1,566		9,556
Proceeds from investor advance		7		—
Proceeds from issuance of notes payable, net		10,000		600
Proceeds from issuance of convertible notes payable, net		1,149		—
Proceeds from contingent payment obligation		4,050		—
Repayment of notes payable		(208)		(5,290)
Repayment of investor advances		(100)		—
Net cash provided by financing activities		21,220		14,331
Effect of exchange rate changes on cash and cash equivalents		(1,419)		3,605
Net decrease in cash and cash equivalents		(5,541)		(10,338)

Cash and cash equivalents, beginning of the period		6,965		15,169
Cash and cash equivalents, end of the period	$	1,424	$	4,831

Supplemental disclosure of cash flow information
Interest payments on notes payable	$	(30)	$	(876)

The accompanying notes are an integral part of these unaudited condensed consolidated financial ~~statements.~~statements

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

For the nine months ended

September 30,


2022

2021
Supplemental schedule of non-cash investing and financing activities:



Cashless warrants and stock options exercise

$
34

$
7
Reclassification of warrant liabilities related to warrants exercised for cash

$
22,625

$
34,412
Reclassification of warrant liabilities related to cashless warrants exercise

$
26,800

$
1,596
Reclassification of warrant liabilities based on authorized shares

$
—

$
56,114
Issuance of common stock and warrants for conversion of debt and accrued interest

$
7,054

$
7,487
Issuance of Series C convertible preferred stock in lieu of debt redemption

$
1,978

$
—
Exercise common stock warrants by debt redemption

$
277

$
—
Reclassification between shares payable and equity

$
250

$
—
Capital expenditures included in accounts payable

$
4

$
327
Capital expenditures included in accounts payable and accrued expenses to related parties and affiliates

$
—

$
559
Issuance of common shares to settle accrued service liability

$
—

$
73


	For the six months ended
	June 30,
	2023		2022
Supplemental schedule of non-cash investing and financing activities:
Cashless warrants and stock options exercise	$	10	$	29
Reclassification of warrant liabilities related to warrants exercised for cash	$	—	$	19,688
Reclassification of warrant liabilities to stockholders’ deficit	$	76,258	$	—
Reclassification of warrant liabilities related to cashless warrants exercise	$	—	$	25,379
Reclassification of investor advances to convertible notes payable	$	661	$	—
Reclassification of investor advances to stockholders' deficit	$	1,203	$	—
Issuance of common stock for conversion of debt and accrued interest	$	9,564	$	2,229
Issuance of Series C convertible preferred stock in lieu of debt redemption	$	1,013	$	—
Series C convertible preferred stock conversion	$	3,562	$	—
Capital expenditures included in accounts payable	$	266	$	49
Reclassification between shares payable and equity	$	—	$	250
Deemed dividend related to warrant modification	$	914	$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

1. Organization and Description of Business

Northwest Biotherapeutics, Inc. and its wholly owned subsidiaries Flaskworks, ~~L.L.C.~~Northwest Biotherapeutics Limited (formerly known as Aracaris Ltd), Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH ~~Aracaris Ltd, Aracaris Capital, Ltd, and Northwest Biotherapeutics B.V.~~ (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer. The Company has developed DCVax® platform technologies for both operable and inoperable solid tumor cancers. The Company ~~is headquartered in Bethesda, Maryland and~~ has wholly owned subsidiaries in Boston, the U.K., in the Netherlands and ~~in Boston, Massachusetts.~~Germany. On August 28, 2020, the Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system designed to close and automate the manufacturing of cell therapy products such as DCVax®. On July 24, 2023, the Company’s wholly-owned subsidiary changed its name from Aracaris Ltd to Northwest Biotherapeutics Limited.

The Company relies upon contract manufacturers for production of its DCVax products, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements.

The Company has completed a Phase 3 clinical trial of its DCVax®-L product for glioblastoma brain cancer, has publicly reported the results in a peer reviewed publication in a medical journal as well as at a medical conference, and is working on prerequisites and preparations for filing an application for regulatory approval of the product.

2. Financial Condition, Going Concern and Management Plans

The Company has incurred annual net operating losses since its inception. The Company had a net loss of ~~$76.7~~$25.1 million for the ~~nine~~six months ended ~~September~~June 30, ~~2022.~~2023. The Company used approximately ~~$43.9~~$22.8 million of cash in its operating activities during the ~~nine~~six months ended ~~September~~June 30, ~~2022.~~2023.

The Company does not expect to generate material revenue in the near future from the sale of products and is subject to all of the risks and uncertainties that are typically faced by biotechnology companies that devote substantially all of their efforts to research and development (“R&D”) and clinical trials and do not yet have commercial products. The Company expects to continue incurring annual losses for the foreseeable future. The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital and other financing requirements until the Company reaches significant revenues. Until that time, the Company will need to obtain additional equity and/or debt financing, especially if the Company experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant increases in expense levels resulting from being a publicly-traded company or from expansion of operations. If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all.

Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern ~~within~~for at least one year from the date of this filing. The ~~condensed~~ consolidated financial statements have been prepared assuming that the Company will continue as a going concern, ~~and~~however, they do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

As previously reported, coronavirus-related difficulties have impacted most aspects of the database lock and the process of analyzing the Phase III trial results, especially with the successive waves of COVID-19 cases in many areas. The independent service firms have had limited capacity, and restrictions on operations. Key experts at certain specialized service providers have been unavailable for periods of time due to illness in their family. Other experts have gone on extended leave due to restrictions on operations. Clinical trial sites have not allowed personnel from the contract research organization managing the trial, or other service providers, to visit the sites for trial matters such as data monitoring and collection activities. Clinical trial site personnel have been unavailable due to being reassigned for COVID-19, and the limited site personnel have had to work under restrictions. Committee processes and regulatory processes have been similarly focused on COVID-19 matters and delayed on other matters. Firms such as the ones storing the Phase III trial tissue samples that are needed for certain analyses, and the firms conducting the analyses have had only limited operations. Even logistical matters such as the shipping of materials have been subjected to substantial restrictions and delays.

3. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All ~~material~~ intercompany balances and transactions have been eliminated. Certain immaterial reclassifications have been made to prior period amounts to conform to the current period presentation.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company ~~prepares~~uses to prepare its annual audited consolidated financial statements. The condensed consolidated balance sheet as of ~~September~~June 30, ~~2022,~~2023, condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2023 and 2022, condensed consolidated statement of stockholders’ deficit for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021,~~2022, and the condensed consolidated statements of cash flows for the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 are not necessarily indicative of results to be expected for the year ending December 31, ~~2022~~2023 or for any future interim period. The condensed consolidated balance sheet at December 31, ~~2021~~2022 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, ~~2021~~2022 and notes thereto included in the Company’s annual report on Form 10-K (the ~~“2021~~“2022 Annual Report”), which was filed with the SEC on ~~March 1, 2022.~~February 28, 2023.

Use of Estimates

In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.

On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets, and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies tofrom those previously disclosed in the ~~2021~~2022 Annual ~~Report.~~Report other than those discussed below.

Sequencing

The Company adopted a sequencing policy under ASC 815-40-35 to determine if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. Certain contracts were classified as liabilities as the result of the instruments containing a potentially indeterminable number of shares and, most recently, due to the Company entering into agreements providing for the potential issuance of more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the earliest grant date of potentially dilutive instruments. Pursuant to ASC 815, issuance of stock-based awards to the Company’s employees, nonemployees or directors are not subject to the sequencing policy.

On January 9, 2023, the Company filed a Certificate of Amendment of its Seventh Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of the State of Delaware, which effected an increase in the Company’s authorized shares of common stock, from 1.2 billion to 1.7 billion, par value $0.001 per share. As a result of this increase in authorized shares, the liability-classified warrants were reclassified to equity. Approximately 141 million warrants, with a value of approximately $76.3 million, to purchase shares of the Company’s common stock were reclassified from liabilities to equity on January 9, 2023. The remaining balance of $1.1 million in warrant liability as of June 30, 2023 was related to certain conditional rights to independently purchase shares from the Company in a future raise of capital (the “Piggy-back Rights”).

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

~~Recently Adopted Accounting Standards~~Modification of Equity Classified Warrants

~~Modifications or Exchanges of Freestanding Equity-Classified Written Call Options~~

In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-ContractsA change in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions ~~or an exchange~~ of a ~~freestanding equity-classified written call option that remains equity classified after~~warrant is accounted for as a modification. For a warrant modification ~~or exchange; (2) how an entity should measure~~accounted for under ASC 815, the effect of a modification ~~or an exchange~~shall be measured as the difference between the fair value of ~~a freestanding equity-classified written call option that remains equity classified after~~the modified warrant and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification ~~or exchange;~~date. The accounting for incremental fair value of the modified warrants over the original warrants is based on the specific facts and ~~(3) how an entity should recognize~~circumstances related to the ~~effect of~~modification. When a modification oris directly attributable to an ~~exchange of a freestanding equity-classified written call option that remains~~ equity ~~classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply~~offering, the ~~amendments prospectively to modifications or exchanges occurring on or after the effective date~~incremental change in fair value of the ~~amendments. Early adoption~~warrants is ~~permitted, including adoption~~accounted for as an equity issuance cost. When a modification is directly attributable to a debt offering, the incremental change in ~~an interim period. On January 1, 2022,~~fair value of the ~~Company adopted this standard without any material impact on~~warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the ~~Company’s condensed consolidated financial statements or disclosures.~~incremental change in fair value is recognized as a deemed dividend.

~~Recent~~Recently Issued Accounting Standards Not Yet Adopted

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions

In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The FASB is issuing this Update (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820.

For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance.

The Company is still evaluating the impact of this pronouncement on the ~~condensed~~ consolidated financial statements.

4. Fair Value Measurements

In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the fair value of liabilities related to certain outstanding warrants, ~~and~~ certain embedded conversion ~~feature~~features associated with convertible debt and the contingent payable to Cognate BioServices on a recurring basis to determine the fair value of ~~the liability.~~these liabilities. ASC 820 ~~also~~ establishes a hierarchy categorizing inputs into three levels used to measure and disclose fair value. The hierarchy gives the highest priority to quoted prices available in active markets and the lowest priority to unobservable inputs. An explanation of each level in the hierarchy is described below:

Level 1 - Unadjusted quoted prices in active markets for identical instruments that are accessible by the Company on the measurement ~~date~~date.

Level 2 - Quoted prices in markets that are not active or inputs which are either directly or indirectly ~~observable~~observable.

Level 3 - Unobservable inputs for the instrument requiring the development of assumptions by the ~~Company~~Company.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of ~~September~~June 30, ~~2022~~2023 and December 31, ~~2021~~2022 (in thousands):


	Fair value measured at September 30, 2022								Fair value measured at June 30, 2023
			Quoted prices in active		Significant other		Significant				Quoted prices in active		Significant other		Significant
	Fair value at		markets		observable inputs		unobservable inputs		Fair value at		markets		observable inputs		unobservable inputs
	September 30, 2022		(Level 1)		(Level 2)		(Level 3)		June 30, 2023		(Level 1)		(Level 2)		(Level 3)
Warrant liability	$	73,650	$	—	$	—	$	73,650	$	1,083	$	—	$	—	$	1,083
Embedded redemption option		922		—		—		922
Contingent payable derivative liability		8,012		—		—		8,012		8,706		—		—		8,706
Share liability										223		—		—		223
Total fair value	$	82,584	$	—	$	—	$	82,584	$	10,012	$	—	$	—	$	10,012


	Fair value measured at December 31, 2021								Fair value measured at December 31, 2022
			Quoted prices in active		Significant other		Significant				Quoted prices in active		Significant other		Significant
	Fair value at		markets		observable inputs		unobservable inputs		Fair value at		markets		observable inputs		unobservable inputs
	December 31, 2021		(Level 1)		(Level 2)		(Level 3)		December 31, 2022		(Level 1)		(Level 2)		(Level 3)
Warrant liability	$	106,784	$	—	$	—	$	106,784	$	80,559	$	—	$	—	$	80,559
Embedded redemption option		988		—		—		988		807		—		—		807
Contingent payable derivative liability		8,232		—		—		8,232		8,668		—		—		8,668
Share liability										678		—		—		678
Total fair value	$	116,004	$	—	$	—	$	116,004	$	90,712	$	—	$	—	$	90,712

There were no transfers between Level 1, 2 or 3 during the ~~nine-month~~six-month period ended ~~September~~June 30, ~~2022.~~2023.

The following table presents changes in Level 3 liabilities measured at fair value for the ~~nine-month~~six-month period ended ~~September~~June 30, ~~2022.~~2023. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).


	Warrant		Embedded		Contingent Payable				Warrant			Embedded		Contingent Payable		Share
	Liability		Redemption Option		Derivative Liability		Total		Liability			Redemption Option		Derivative Liability		Liability		Total
Balance - January 1, 2022	$	106,784	$	988	$	8,232	$	116,004
Additional warrant liability		184		7		—		191
Debt redemption		—		(69)		—		(69)
Balance - January 1, 2023									$	80,559		$	807	$	8,668	$	678	$	90,712
Additional share liability										—			—		—		663		663
Redemption of share liability										—			—		—		(1,071)		(1,071)
Reclassification of warrant liabilities		(49,425)		—		—		(49,425)		(76,258)			—		—		—		(76,258)
Change in fair value		16,107		(4)		(220)		15,883		(3,218)			(807)		38		(47)		(4,034)
Balance - September 30, 2022	$	73,650	$	922	$	8,012	$	82,584
Balance - June 30, 2023									$	1,083	⁽¹⁾	$	—	$	8,706	$	223	$	10,012

(1)

The remaining balance of $1.1 million in warrant liability as of June 30, 2023 was related to certain conditional rights to independently purchase shares from the Company in a future raise of capital (the “Piggy-back Rights”). The Company accounted for the Piggy-back Rights as a freestanding financial instrument, which was classified as a liability at fair value on the Condensed Consolidated Balance Sheet

~~A summary of~~On January 9, 2023, the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 ofCompany reclassified the fair value ~~hierarchy as~~ of ~~September 30,~~the warrant liability of $76.3 million into the additional paid-in capital. The change in fair value of the common stock warrant liability of $2.3 million between December 31, 2022 and ~~December 31, 2021~~January 9, 2023 is ~~as follows:~~reflected in “Change in fair value of derivative liabilities” in the accompanying condensed consolidated statements of comprehensive loss for the six months ended June 30, 2023.

As of September 30, 2022

Warrant

Contingent Payable


Liability

Derivative Liability

Strike price

$
0.30

$
0.71
*
Contractual term (years)

1.5

0.6

Volatility (annual)

69
%

82
%
Risk-free rate

3.8
%

3.9
%
Dividend yield (per share)

0
%

0
%

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

As of December 31, 2021


Warrant

Contingent Payable


Liability

Derivative Liability

Strike price

$
0.30

$
0.70
*
Contractual term (years)

1.0

1.6

Volatility (annual)

90
%

72
%
Risk-free rate

0.1
%

0.6
%
Dividend yield (per share)

0
%

0
%

~~Contingent based on current stock price as of September 30, 2022 and December 31, 2021.~~

A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of June 30, 2023, January 9, 2023 (the reclassification date) and December 31, 2022 is as follows:


	As of June 30, 2023						As of January 9, 2023
	Share			Contingent Payable			Warrant
	Liability			Derivative Liability			Liability
Strike price	$	0.60		$	0.57	*	$	0.31
Contractual term (years)		0.07			1.24			1.46
Volatility (annual)		60	%		61	%		87	%
Risk-free rate		4.3	%		5.5	%		4.3	%
Dividend yield (per share)		0	%		0	%		0	%


	As of December 31, 2022
	Warrant			Share			Contingent Payable
	Liability			Liability			Derivative Liability
Strike price	$	0.31		$	0.78	*	$	0.78	*
Contractual term (years)		1.5			0.1			0.6
Volatility (annual)		86	%		76	%		77	%
Risk-free rate		4.3	%		2.0	%		4.8	%
Dividend yield (per share)		0	%		0	%		0	%

*	The strike price assumes the current stock price as of June 30, 2023 and December 31, 2022

The key unobservable inputs for Piggy-back rights that was included in the warrant liability as of June 30, 2023 and December 31, 2022 was the assumption of the estimated remaining life which was based on the estimate of the next qualified financing.

5. Stock-based Compensation

The following table summarizes total ~~amounts of~~ stock-based compensation ~~that were expensed during~~expense for the three and ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022 (in thousands).


	For the three months ended				For the six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Research and development	$	147	$	641	$	444	$	1,151
Research and development - related party
Milestones achieved ⁽¹⁾		—		1,410		520		1,410
Future milestones ⁽²⁾		40		3,930		140		3,930
General and administrative		90		(218)		107		(111)
Total stock-based compensation expense	$	277	$	5,763	$	1,211	$	6,380

The related party amounts were for milestone incentives that either were earned or are deemed probable to be achieved in the future and become issuable at that time (as detailed below in Restricted Stock Awards). During the three and nine months ended September 30, 2022, for three milestones that were completed, the Company recognized and expensed the remaining $0.2 million, for a total of $0.7 million, for 1.0 million shares and $2.1 million for the 2.5 million shares, respectively. For seven further milestones that are anticipated to be achieved and earned in the future, the Company recognized and expensed (but did not issue) the pro-rata portion on the remaining potential milestone stock awards during the three and nine months ended September 30, 2022, of $1.2 million and $4.6 million, respectively.

For the three months ended

For the nine months ended

September 30,

September 30,


2022

2021

2022

2021
Research and development

$
921

$
982

$
2,072

$
7,224
Research and development - related party

1,400

—

6,740

—
General and administrative

1,040

281

929

7,408
Total stock-based compensation expense

$
3,361

$
1,263

$
9,741

$
14,632

(1)

During the six months ended June 30, 2023, the Company recognized the remaining $0.5 million stock-based compensation related to the achieved milestone (obtaining a commercial manufacturing license from the MHRA). The Company had previously recognized $1.6 million stock-based compensation as of December 31, 2022.

~~During~~The $1.4 million expense recognized in 2022 covers 2 one-time milestones: 2 required licenses for the ~~nine months ended September 30, 2022,~~Sawston facility (licenses from the ~~Company reversed approximately $0.9 million~~Human Tissue Authority and ~~$0.3 million of stock-based compensation expense in research~~from the MHRA for manufacturing for clinical trials and ~~development and general and administrative, respectively, which were related to the cancellation of certain unvested performance-based awards.~~

The Black-Scholes option pricing model is used to estimate the fair value of stock options granted. The weighted average assumptions used in calculating the fair values of stock options that were granted during the nine months ended September 30, 2022 was as follows:

For the nine months

ended

September 30, 2022

Exercise price

$
0.65

Expected term (years)

3.9

Expected stock price volatility

99
%
Risk-free rate

3.3
%
Dividend yield (per share)

0
%

~~The total unrecognized compensation cost was approximately $5.4 million as of September 30, 2022 and will be recognized over the next 1.25 years.~~

compassionate use cases).

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

(2)	During the three and six months ended June 30, 2023, the Company recognized and expensed (but did not issue shares for) the pro-rata portion of the remaining one-time milestone stock awards for drafting key portions of the application for product approval of $40,000 and $140,000, respectively.

During the three and six months ended June 30, 2022, the Company recognized and expensed (but did not issue shares for) the pro-rata portion of 6 one-time milestones: 5 workstreams (Comparability, Stability, Potency, Product Profile and Fill/Finish) and one-time milestone for drafting key portions of the application for product approval of $3.9 million and $3.9 million, respectively.

The total unrecognized stock compensation cost was approximately $0.5 million as of June 30, 2023 and will be recognized over the next 1.5 years.

Stock Options

The following table summarizes stock option activity for the Company’s option plans during the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 (amount in thousands, except per share number):


				Weighted Average						Weighted Average
		Weighted		Remaining				Weighted		Remaining
	Number of	Average		Contractual Life	Total Intrinsic		Number of	Average		Contractual Life	Total Intrinsic
	Shares	Exercise Price		(in years)	Value		Shares	Exercise Price		(in years)	Value
Outstanding as of January 1, 2022	304,847	$	0.33	8.0	$	114,803
Granted⁽¹⁾	8,005		0.65	7.0
Outstanding as of January 1, 2023							301,263	$	0.34	7.0	$	135,225
Cashless exercised	(8,187)		0.27				(1,827)		0.41	—		—
Forfeited/expired	(69)		10.65
Outstanding as of September 30, 2022	304,596	$	0.34	7.3	$	114,617
Options vested ⁽²⁾	281,963	$	0.33	7.3	$	108,301
Outstanding as of June 30, 2023							299,436	$	0.33	6.5	$	73,083
Options vested ⁽¹⁾							281,278	$	0.33	6.5	$	69,223

(1)

~~Awards granted~~An aggregate 153 million stock options held by Ms. Linda Powers, the Company’s Chief Executive Officer, and Mr. Leslie Goldman, the Company’s Senior Vice President, are subject to ~~Flaskworks employees and consultants.~~an agreement (the “Blocker Letter Agreement”) under which they cannot exercise any options or warrants except upon at least 61 days’ prior notice.

~~(2)~~

~~Approximately 236.6 million options are not exercisable until at least November 30, 2022.~~

The existing options and warrants held by Ms. Linda Powers, the Company’s Chief Executive Officer, and Mr. Leslie Goldman, the Company’s Senior Vice President, General Counsel are subject to an agreement under which they cannot be exercised except upon at least 61 days’ prior notice.

Restricted Stock Awards

During April 2022, the Company’s Board approved, and the Company entered into a Statement of Work #6 (the “SOW 6”) with Advent BioServices, a related party of the Company, for five workstreams that are prerequisites for an application for regulatory approval of DCVax-L, for three required licenses for the Sawston facility , and for drafting of key portions of the application ~~and~~ for ~~three required licenses for the Sawston facility.~~approval. The SOW provides for baseline costs and for milestone incentives for successful completion of each of the workstreams, for the completion and submission of ~~the~~each application for product approval, and for obtaining regulatory approval of each of the three Sawston licenses. The milestone incentives will be a combination of cash and stock and ~~will~~are not be paid until they are achieved. On September 26, 2022, the Company amended the SOW6 (the “Amended SOW6”) to (1) extend the service period through September 30, 2023, and (2) clarify the assessment and application of the milestones, and (3) add a sixth ~~workstream ( The~~workstream. (The potential cost for all unearned stock awards for milestones not yet achieved was re-measured on the modification date and will be further re-measured until the date the milestone award is achieved and the stock awards are earned.) If all of the 10 one-time milestones are achieved (i.e., for all 6six workstreams that are prerequisites for an application for product approval, for obtaining all three licenses required for the Sawston facility, and for the completion ~~and submission~~of key portions of the application for product ~~approval, and for all 3 licenses required for the Sawston facility)~~approval), the aggregate stock-based compensation under the Amended ~~SOW6~~SOW 6 will be 13.5 million shares (including the shares already earned and issued for the milestones already achieved)~~. As of September 30, 2022, the 13.5 million shares had~~ for an aggregate fair value of ~~$9.9~~$10.1 million.

~~During the three and nine months ended September 30,~~As of December 31, 2022, ~~the Company recognized and expensed $0.2 million and $2.0 million, respectively, related to the cash component of~~seven milestones were completed, ~~and earned during the period. The three completed milestones included one~~including five of the workstreams, and the regulatory approvals of two licenses required for the Sawston facility.

~~For the cash components of seven further milestones under Amended SOW6 that are anticipated to be achieved~~ An eighth milestone was partly completed and earned in the future, the Company recognized and expensed (but did not pay) during the three and nine months ended September 30, 2022, the pro-rata share of $1.3 million and $3.3 million, respectively.

~~For~~ the stock component of that milestone was earned, but the ~~three milestones~~cash portion of that ~~were completed and earned during~~eighth milestone was not yet earned.

During the ~~three and nine~~six months ended ~~September~~June 30, ~~2022 (as also described above, in Stock Based Compensation),~~2023, the ~~Company recognized~~eighth milestone workstream for Mechanism of Action and ~~expensed~~ the ~~remaining $0.2 million,~~milestone for ~~a total of $0.7 million, for 1.0 shares million and $2.1 million for~~obtaining the ~~2.5 million shares, respectively.~~commercial manufacturing license from the MHRA were completed. For this manufacturing license milestone, the Company

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

recognized the remaining $0.5 million in expense in the condensed consolidated statements of operations and comprehensive loss and issued 3.0 million common shares.

For ~~seven further milestones~~the remaining one-time milestone that ~~are~~is anticipated to be achieved and earned in the future, the Company recognized and expensed (but did not issue) the pro-rata portion onof the remaining potential milestone stock awards during the three and ~~nine~~six months ended ~~September~~June 30, ~~2022,~~2023, of ~~$1.2~~$40,000 and $0.1 million, ~~and $4.6 million, respectively (as also described above, in Stock Based Compensation).~~respectively.

Other Service Agreement

On ~~August 22, 2022,~~March 16, 2023, the Company issued ~~1.5 million~~8,000 shares of ~~common~~Series C convertible preferred stock to ~~certain~~an unrelated ~~vendors~~vendor who provided professional services for the Company. The fair value of the ~~common shares~~Series C convertible preferred stock on the issuance date was ~~approximate $1~~approximately $0.1 million, which will be expensed over a four-month service period. During the three and ~~was~~six months ended June 30, 2023, the Company recognized approximately $89,000 and $0.1 million, respectively as part of general and administrative expenses.

6. Property, Plant and Equipment

Property, plant and equipment consist of the following at June 30, 2023 and December 31, 2022 (in thousands):


	June 30,		December 31,		Estimated
	2023		2022		Useful Life
Leasehold improvements	$	17,250	$	13,070	Lesser of lease term or estimated useful life
Office furniture and equipment		455		300	3-5 years
Computer and manufacturing equipment and software		2,495		2,238	3-5 years
Land in the United Kingdom		86		82	NA
		20,286		15,690	NA
Less: accumulated depreciation		(3,000)		(2,272)
Total property, plant and equipment, net	$	17,286	$	13,418

Construction in progress	$	—	$	2,028

The construction works related to expanding the operational portion of its UK facility (Phase 1B) were completed and placed in service as of June 30, 2023. All costs associated with the Phase 1B build out were reclassified from construction in progress to leasehold improvements effective June 2023 and are being amortized over the estimated useful life of the facility.

Depreciation expense was approximately $0.7 million and $0.6 million for the six months ended June 30, 2023, and 2022, respectively.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

~~6. Notes Payable~~7. Outstanding Debt

The following two tables summarize outstanding debt as of ~~September~~June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively (amount in thousands):


		Stated									Embedded					Stated
		Interest			Conversion				Remaining		Redemption		Carrying			Interest			Conversion					Remaining		Carrying
	Maturity Date	Rate			Price		Face Value		Debt Discount		Option		Value		Maturity Date	Rate			Price			Face Value		Debt Discount		Value
Short term convertible notes payable
6% unsecured	Due		6	%	$	3.09	$	135	$	—	$	—	$	135	Due		6	%	$	3.09		$	135	$	—	$	135
8% unsecured															1/31/2024		8	%		0.55	*		900		(177)		723
8% unsecured															6/30/2024		8	%		0.50	*		1,000		—		1,000
								135		—		—		135									2,035		(177)		1,858
Short term notes payable
8% unsecured	Various		8	%		N/A		18,470		(1,890)		922		17,502	Various		8	%		N/A			8,253		(413)		7,840
9% unsecured	Various		9	%		N/A		1,827		—		—		1,827
12% unsecured	On Demand		12	%		N/A		703		—		—		703	On Demand		12	%		N/A			562		—		562
								21,000		(1,890)		922		20,032									8,815		(413)		8,402
Long term notes payable
8% unsecured	7/26/2024		8	%		N/A		5,505		(501)		—		5,004	7/26/2024		8	%		N/A			16,117		(1,121)		14,996
6% secured	3/25/2025		6	%		N/A		938		—		—		938	3/25/2025		6	%		N/A			748		—		748
								6,443		(501)		—		5,942									16,865		(1,121)		15,744

Ending balance as of September 30, 2022							$	27,578	$	(2,391)	$	922	$	26,109
Ending balance as of June 30, 2023																						$	27,715	$	(1,711)	$	26,004

*The 8% convertible notes are convertible into Series C preferred shares at $12.50 - $13.75 per share. Each Series C preferred share is convertible into common shares with 30 days’ restriction period. The conversion price in common share equivalent is at $0.50 and $0.55 per share.


		Stated									Embedded					Stated									Embedded
		Interest			Conversion				Remaining		Redemption		Carrying			Interest			Conversion				Remaining		Redemption		Carrying
	Maturity Date	Rate			Price		Face Value		Debt Discount		Option		Value		Maturity Date	Rate			Price		Face Value		Debt Discount		Option		Value
Short term convertible notes payable
6% unsecured	Due		6	%	$	3.09	$	135	$	—	$	—	$	135	Due		6	%	$	3.09	$	135	$	—	$	—	$	135
								135		—		—		135								135		—		—		135
Short term notes payable
8% unsecured	Various		8	%		N/A		2,320		(118)		—		2,202	Various		8	%		N/A		14,540		(1,300)		807		14,047
9% unsecured	Various		9	%		N/A		4,232		(80)		47		4,199	Various		9	%		N/A		793		—		—		793
12% unsecured	On Demand		12	%		N/A		703		—		—		703	On Demand		12	%		N/A		563		—		—		563
								7,255		(198)		47		7,104								15,896		(1,300)		807		15,403
Long term notes payable
1% unsecured	Various		1	%		N/A		433		—		—		433
8% unsecured	9/22/2023		8	%		N/A		25,938		(3,638)		941		23,241	7/26/2024		8	%		N/A		5,505		(432)		—		5,073
6% secured	3/25/2025		6	%		N/A		1,482		—		—		1,482	3/25/2025		6	%		N/A		918		—		—		918
								27,853		(3,638)		941		25,156								6,423		(432)		—		5,991

Ending balance as of December 31, 2021							$	35,243	$	(3,836)	$	988	$	32,395
Ending balance as of December 31, 2022																					$	22,454	$	(1,732)	$	807	$	21,529

On ~~September 26, 2022,~~March 2, 2023, the Company entered into a Commercial Loan Agreement (the “Commercial Loan”) with a commercial lender for an aggregate principal amount of ~~$5.5~~$11.0 million. The Commercial Loan bears interest at 8% per annum with a 22-month term. There are no principal repayments during the first 8eight months of the term. The Commercial Loan is amortized in 14 installments starting on ~~May 26,~~November 2, 2023. The Commercial Loan carries an original issue discount of ~~$0.5~~$1.0 million.

In April 2023, the Company entered into several ten-month convertible notes (the “April Convertible Notes”) with multiple investors (the “Holders”) with an aggregate principal amount of $0.9 million for a purchase price of $0.8 million. The April Convertible Notes bear interest at 8% per annum, and are convertible into Series C preferred shares at $13.75 per share at the Holders’ sole option. The Series C preferred shares are convertible into common stock 30 days after the debt conversion date. Each Series C preferred share is convertible into 25 shares of common stock. The Company reclassed $0.7 million Investor advances that was received from the Holders in December 2022 to Convertible notes payable on the condensed consolidated balance sheet as of June 30, 2023. As a result, the Company received net cash proceeds of $0.1 million.

1516

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

~~During~~As consideration for entering into the ~~nine months ended September~~convertible note agreements, the Company also agreed to amend the investors’ existing outstanding warrants. The exercise price of certain warrants was amended from $2.00 per share to $0.55 per share, and the maturity date was extended for additional 9 months. The incremental change in fair value resulting from the amendment was approximately $0.2 million, which was recognized as an additional debt discount to the April Convertible Notes.

On June 30, ~~2022,~~2023, the Company entered into ~~multiple four-month~~a one-year convertible note ~~agreements~~ (the ~~“Notes”~~“June Convertible Note”) with ~~various~~an individual ~~lenders~~investor (the ~~“Holders”~~“Holder”) with an aggregate principal amount of ~~$0.6 million for net proceeds of $0.6~~$1.0 million. The ~~Notes have a 9% interest rate, a 5% original issue discount (“OID”), and contain a conditional right to independently purchase shares~~Company received $1.0 million cash from the ~~Company in a future raise of Capital (the “Piggy-back Right”), under which~~June Convertible Note. The June Convertible Note bears interest at 8% per annum, and is convertible into Series C preferred shares at $12.50 per share at the Company agrees that if it (i) publicly releases top line data from the Phase III trial of its DCVax®-L vaccine (such eventuality, the “Release”) and (ii) consummates the first private placement offering of itsHolder's sole option. The Series C preferred shares are convertible into common stock ~~following such Release (the “Next Offering”), then Holder shall have~~30 days after the ~~conditional right, at its sole option, typically exercisable within seven (7) days following the Next Offering, to independently purchase from the Company up to a number~~debt conversion date. Each Series C preferred share is convertible into 25 shares of shares equal in value to (a) 50% of the principal amount of the loan, (b) 50% of the value of the exercised warrant shares, and (c) exchange some or all of the outstanding loan amount for a variable number of shares (the “Contingent Rights”). The Contingent Right (a) and (b) above shall be priced at a 12% discount from the Next Offering, resulting in either an elimination of, or a reduced cash amount repayable under the loan agreement. The Company accounted for the Contingent Right (a) and (b) as a freestanding financial instrument, which was classified as a liability at fair value on the Condensed Consolidated Balance Sheet with changes in fair value recognized in the Condensed Consolidated Statement of Operations. The Company accounted for the Contingent Right (c) as an embedded derivative liability at fair value, which requires it to be bifurcated, with changes in fair value recognized in the Condensed Consolidated Statement of Operations.common stock.

During the ~~nine~~six months ended ~~September~~June 30, ~~2022,~~2023, the Company issued approximately ~~10.4~~15.2 million shares of common stock atwith a fair value of ~~$7.6~~$9.6 million to certain lenders in lieu of cash ~~payments.~~payments of $7.4 million of debt, including $0.7 million of accrued interest. In addition, pursuant to exchange agreements executed with various holders, the Company is required to potentially issue additional common stock (the “Share liability”) if the stock price is less than the price defined in the exchange agreement as of the true-up date. During the six months ended June 30, 2023, the Company extinguished Share liabilities of $1.1 million and recognized an additional $0.7 million in Share liabilities. The Company recognized an approximately ~~$0.2~~$1.8 million debt extinguishment ~~loss.~~loss during the six months ended June 30, 2023 from the debt redemption.

During the ~~nine~~six months ended ~~September~~June 30, ~~2022~~,2023, the Company ~~made aggregate cash payments~~recognized $0.8 million change in fair value of ~~$6.3 million~~embedded redemption option as this embedded feature had de minimis value based on ~~notes payable, including $0.9 million~~the remaining life of ~~interest payment.~~the note and the next qualified financing.

During the ~~nine~~six months ended ~~September~~June 30, ~~2022, the Company entered into multiple note extension agreements whereby the maturity date of the notes was extended for an additional~~ ~~two-four months.~~

The Company received two loans under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act’s Paycheck Protection Program (“PPP”) in 2021 for the amount of $0.4 million. On February 22, 2022, the PPP loans were approved for forgiveness. The Company recorded approximately $0.4 million debt extinguishment gain from the forgiveness of these PPP loans.

For the three months ended September 30, 2022 and 2021, interest expense related to notes payable totaled approximately $1.1 million and $0.7 million including amortization of debt discounts totaling $0.6 million and $0.2 million, respectively. The Company also accrued approximately $0.4 million interest expense related to German tax during the three months ended September 30, 2022 (see note 11).

For the nine months ended September 30, 2022 and 2021, interest expense related to notes payable totaled approximately $4.5 million and $2.1 million including amortization of debt discounts totaling $2.1 million and $1.4 million, respectively. The Company also accrued approximately $0.4 million interest expense related to German taxes during the nine months ended September 30, 2022 (see note 11).

~~Debt Redemption~~

~~In July 2022,~~2023, the Company issued approximately ~~2.8 million~~ 56,000 shares of ~~common~~Series C preferred stock with a fair value of $1.0 million to certain lenders in lieu of cash payments ~~on $1.7~~of $0.9 million ~~of outstanding debt.~~

~~During the three months ended September 30, 2022, the Company extinguished approximately $2.0 million~~in debt, including $0.1 million of accrued interest. The Company recognized an approximately $0.1 million debt extinguishment loss.

For the three months ended June 30, 2023 and 2022, interest ~~in lieu~~expense related to outstanding debt totaled approximately $1.3 million and $1.4 million including amortization of ~~partial consideration received for issuance~~debt discounts totaling $0.7 million and $0.7 million, respectively.

For the six months ended June 30, 2023 and 2022, interest expense related to outstanding debt totaled approximately $2.3 million and $3.3 million including amortization of ~~Series C convertible preferred stock.~~debt discounts totaling $1.3 million and $1.5 million, respectively.

8. Net Loss per Share Applicable to Common Stockholders

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share would be computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Because of the net loss from operations for each period, inclusion of such securities in the computation of loss per share would be anti-dilutive and thus they are excluded. Potentially dilutive weighted average common shares include common stock potentially issuable under the Company’s convertible notes and preferred stock, warrants and vested and unvested stock options.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):

1617

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS


	For the six months ended
	June 30,
	2023	2022
Series C convertible preferred stock	38,638	—
Common stock options	299,436	309,512
Common stock warrants	117,863	153,110
Convertible notes and accrued interest	3,748	76
Potentially dilutive securities	459,685	462,698

9. Related Party Transactions

The Company had three operational programs with Advent: (a) an ongoing manufacturing program at the GMP facility in London, (b) an ongoing development and manufacturing program at the Sawston GMP facility, and (c) a one-time program for specialized work, organized into 10 sets of one-time milestones, for the following:

●

Qualifying for and obtaining 3 required licenses for the Sawston facility: a license from the Human Tissue Authority to collect and process human cells and tissues, a license from the MHRA for manufacturing for clinical trials and compassionate use cases, and a license from the MHRA for commercial manufacturing.

●	6 workstreams relating to product matters required for an application for regulatory approval of DCVax-L, including Comparability, Stability, Potency, Product Profile, Mechanism of Action and Fill/Finish.

●	Drafting of key portions of the application for product approval itself.

Each of the three operational programs is covered by a separate contract. The ongoing manufacturing in the London facility is covered by a Manufacturing Services Agreement (“MSA”) entered into on May 14, 2018. The development and manufacturing program at the Sawston facility is covered by an Ancillary Services Agreement entered into on November 18, 2019. The specialized work associated with the 10 one-time milestones is covered by an SOW 6 entered into under the Ancillary Services Agreement as of April 1, 2022 and amended on September 26, 2022.

The Ancillary Services Agreement establishes a structure under which the Company and Advent negotiate and agree upon the scope and terms for Statements of Work (“SOWs”) for facility development activities and compassionate use program activities. After an SOW is agreed and approved by the Company, Advent will proceed with, or continue, the applicable services and will invoice the Company pursuant to the SOW. Since both the facility development and the compassionate use program involve pioneering and uncertainties in most aspects, the invoicing under the Ancillary Services Agreement is on the basis of costs incurred plus fifteen percent. The SOWs may involve ongoing activities or specialized one-time projects and related one-time milestone payments. The current Ancillary Services Agreement ended in September 2023. The Company subsequently extended the term by 12 months to July 2024 with no other changes.

SOW 6 provides for ongoing baseline costs for manufacturing at the Sawston facility and one-time milestone incentives for (a) regulatory approval of each of the 3 licenses required for the Sawston facility, (b) successful completion of each of the 6 workstreams and (c) completion of drafting key portions of an application for product approval. The milestone incentives are a combination of cash and stock, and are not paid until the milestone is achieved and earned.

During the six months ended June 30, 2023, the Company paid an aggregate of $2.0 million in cash, of which $1.0 million was related to two milestones that were completed and fully expensed but unpaid as of December 31, 2022, and the other $1.0 million was partial payment for one milestone (obtaining a commercial manufacturing license from the MHRA) that was completed as of March 20, 2023. The Company issued 3.0 million common shares as a result of completion of the one-time milestone (obtaining a commercial manufacturing license from the MHRA) at fair value of $2.1 million, of which $0.5 million was recognized during the six months ended June 30, 2023 and $1.6 million had already been recognized (but not paid) in 2022. During the six months ended June 30, 2023, the Company also expensed (but did not pay) an aggregate of $0.5 million related to completed cash milestone payments; the Company also expensed (but did not pay) an aggregate of $0.2 million related to future cash milestone payments that the Company anticipates will be

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

~~7. Net Earnings (Loss) per Share Applicable to Common Stockholders~~

Basic earnings (loss) per common share is computed by dividing net earnings (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per common share is computed similar to basic earnings (loss) per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Diluted weighted average common shares include common stock potentially issuable under the Company’s convertible notes, warrants and vested and unvested stock options.

~~For the three and nine months ended September 30, 2021, net income was adjusted for gain from change in fair value of warrant liabilities.~~

~~The following table sets forth the computation of earnings (loss) per share (amounts in thousands):~~

For the three months ended

For the nine months ended

September 30,

September 30,

2022

2021

2022

2021
Net earnings (loss) - basic

$
(32,852)

$
4,410

$
(76,734)

$
287
Reversal of gain due to change in fair value of warrant liability

—

(17,500)

—

(35,063)
Net loss - diluted

(32,852)

(13,090)

(76,734)

(34,776)

Weighted average shares outstanding - basic

1,040,982

875,963

1,001,703

854,276
Diluted shares- Options

—

40,189

—

41,773
Diluted shares- Warrants

—

219,535

—

203,474
Convertible notes and interest

—

75

—

75
Weighted average shares outstanding - diluted

1,040,982

1,135,762

1,001,703

1,099,598

~~The following securities were not included in the diluted net earnings (loss) per share calculation because their effect was anti-dilutive as of the periods presented (in thousands):~~

For the nine months ended

September 30,

2022

2021
Series C convertible preferred stock

22,129

—
Common stock options

304,596

257,005
Common stock warrants

145,417

56,712
Convertible notes and accrued interest

76

—
Potentially dilutive securities

472,218

313,717

~~8. Related Party Transactions~~

~~Advent BioServices Agreement~~

The Company has a Manufacturing Services Agreement with Advent BioServices (“Advent”) for the manufacture of DCVax-L products at an existing facility in London, as previously reported. The Company also has an Ancillary Services Agreement with Advent, which establishes a structure under which Advent submits Statements of Work (“SOWs”) for activities related to the development of the Sawston facility and the compassionate use activities in the UK, as previously reported. The Ancillary Services Agreement had an original term of eight months, which ended in July 2020. The Company extended the term by 12 months to July 2021 and another 12 months to July 2022, with no other changes, and recently extended it for another 12 months to July 2023.

During April 2022, the Company’s Board approved and the Company entered into a SOW 6 with Advent BioServices for five workstreams that are prerequisites for an application for regulatory approval of DCVax-L, for drafting of key portions of the application and for three required licenses for the Sawston facility. On September 26, 2022, the Company amended the SOW 6 (the “Amended SOW 6”) to (1) extend the service period through September 30, 2023, (2) add a sixth workstream and (3) clarify the assessment and

~~Table of Contents~~

~~NORTHWEST BIOTHERAPEUTICS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED STATEMENTS~~

application of milestones. The SOW provides for baseline costs and for milestone incentives for successful completion of each of the workstreams, for the completion and submission of the application for product approval, and for regulatory approval of each of the 3 licenses required for the Sawston facility. The milestone incentives will be a combination of cash and stock and will not be paid until they are achieved and ~~earned. During the nine months ended September 30, 2022, the Company paid an aggregate of $1.5 million in cash~~earned, and ~~2.5 million shares combined for completion of 3 milestones, and the Company also expensed an aggregate of $3.8 million related to future cash milestone payments and $4.6~~$0.1 million related to fair value of future shares milestone payments that the Company anticipates will be achieved and earned over the course of the contract period.

The following table summarizes total research and development costs from Advent for the three and six months ended June 30, 2023 and 2022, respectively (in thousands).


	For the three months ended				For the six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Advent BioServices
Manufacturing cost in London	$	1,660	$	1,424	$	3,303	$	2,827
Manufacturing cost at Sawston facility		2,098		1,276		3,810		2,701
SOW 6 one-time milestones - Shares
Expensed and paid (milestone complete) ⁽¹⁾		—		1,410		520		1,410
Expensed but unpaid, not yet due (milestone not yet complete) ⁽²⁾⁽³⁾		40		3,930		140		3,930
SOW 6 one-time milestones - Cash
Expensed and paid (milestone complete) ⁽⁴⁾		—		500		—		500
Expensed and due, but unpaid (milestone complete) ⁽⁵⁾		—		1,000		550		1,000
Expensed but unpaid, not yet due (milestone not yet complete) ⁽⁶⁾		60		2,314		210		2,314
Total	$	3,858	$	11,854	$	8,533	$	14,682

(1)

The payment for the six months ended June 30, 2023 covers the one-time milestone for obtaining a commercial manufacturing license from the MHRA. The payment for the six months ended June 30, 2022 also covers 2 other one-time milestones: 2 required licenses for the Sawston facility (licenses from the Human Tissue Authority and from the MHRA for manufacturing for clinical trials and compassionate use cases).

(2)	The expense for the six months ended June 30, 2023 covers the one-time milestone for drafting key portions of the application for product approval.

(3)	The expense for the six months ended June 30, 2022 covers 6 one-time milestones: 5 workstreams (Comparability, Stability, Potency, Product Profile and Fill/Finish) and 1 one-time milestone for drafting key portions of the application for product approval.

(4)	This covers one-time milestone: a required license for the Sawston facility from the Human Tissue Authority.

(5)

The expense for the six months ended June 30, 2023 covers the one-time milestone workstream: Mechanism of Action. The expense for the six months ended June 30, 2022 covers one-time milestone: a required license for the Sawston facility from the MHRA for manufacturing for clinical trials and compassionate use cases.

(6)

The expense for the six months ended June 30, 2023 covers the one-time milestone for drafting key portions of the application for product approval. The expense for the six months ended June 30, 2022 covers 6 one-time milestones: 5 workstreams (Comparability, Stability, Potency, Product Profile and Fill/Finish) and one-time milestone for drafting key portions of the application for product approval.

Advent BioServices Sublease Agreement

On December 31, 2021, the Company entered into a Sub-lease Agreement (the “Agreement”) with Advent. The Agreement permits use by Advent of a portion of the space in the Sawston facility, which is leased by the Company under a separate head lease with a different counterparty (Huawei) that commenced on December 14, 2018. The Company subleased approximately 14,459 square feet of the 88,000 square foot building interior space, plus corresponding exterior support space and parking. The lease payments amount under the Agreement are two times the amount payable by the Company under the head lease (which is currently £5.75 ~~(approximate $7.76~~or approximately $7.28 per square foot based on exchange rate as of ~~December 31, 2021) rate per square foot payable under the head lease,~~June 30, 2023), but subject to a cap of $10 per square foot. Accordingly, the monthly lease payments under the Sublease are ~~calculated~~ based on ~~$144,590~~$145,000 annually for ~~2022.~~2023. The total lease payments paid by the Company to Huawei for the 88,000 square foot facility, exterior spaces and parking under the head lease are ~~500,000 pounds~~£500,000 (approximately $633,000) per year. The term of the Agreement shall end on the same date as the head lease term ends.

~~During the three and nine months ended September 30, 2022, the Company recognized sub-lease income of $37,000 and $110,000, respectively.~~

~~Related Party Expenses and Accounts Payable~~

~~During the nine months ended September 30, 2022 and 2021, the Company capitalized $28,000 and $1.4 million costs, related to the Sawston facility buildout, invoiced by Advent.~~

~~The following table summarizes outstanding unpaid accounts payable and accrued expenses held by related parties as of September 30, 2022 and December 31, 2021 (amount in thousands).~~ ~~These unpaid amounts include part of the expenses reported in the above section. The 2021 balance also included certain expenses incurred in prior periods.~~

September 30,

December 31,

2022

2021
Advent BioServices – amount invoiced

$
892

$
3,046
Advent BioServices – amount accrued for future milestones

3,806

—
Accounts payable and accrued expenses to Advent BioServices

$
4,698

$
3,046

As of September 30, 2022, there was approximately $0.9 million of unpaid Board compensation that was also included in the accounts payable to related party on the condensed consolidated balance sheets.

~~9. Preferred Stock~~

~~Series C Convertible Preferred Stock~~

On July 20, 2022, the Company filed a Certificate of Elimination with the Secretary of State of the State of Delaware with respect to the Company’s Series A Preferred Stock and Series B Preferred Stock pursuant to which both series were eliminated and returned to the status of authorized and unissued preferred shares of the Company, as there are no longer any Series A or Series B Preferred shares outstanding.

Also on July 20, 2022, the Company filed the Certificate of Designations for Series C Preferred Stock (the “Series C Certificate of Designations”) with the Secretary of State of the State of Delaware, setting forth the terms of the Series C Preferred Stock. The Series C Certificate of Designations, effective as of July 20, 2022, that was created out of the authorized and unissued shares of preferred stock

1819

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

~~of the Company, provides for 10,000,000 shares, par value $0.001 per share, and establishes the rights, preferences and privileges of the Series C.~~

During the three and six months ended ~~September~~June 30, ~~2022,~~2023, the Company recognized sub-lease income of $36,000 and $72,000, respectively.

Related Party Accounts Payable

As of June 30, 2023, there was approximately $0.2 million of unpaid board compensation to one of our Directors that was included in the accounts payable to related party on the condensed consolidated balance sheets.

As of June 30, 2023, there were outstanding unpaid accounts payable and accrued expenses owed to Advent as summarized in the following table (in thousands). These unpaid amounts are part of the Related Party expenses reported in the above section.


	June 30,		December 31,
	2023		2022
Advent BioServices - amount invoiced but unpaid	$	2,855	$	1,844
Advent BioServices - amount accrued but unpaid		3,496		4,736
Total payable and accrued, but unpaid to Advent BioServices	$	6,351	$	6,580

10. Preferred Stock

Series C Convertible Preferred Stock

During the six months ended June 30, 2023, the Company entered into various Subscription Agreements (the “Series C Subscription Agreements”) with certain investors (the “Series C Investors”). Pursuant to the Series C Subscription Agreements, the Company issued the Series C Investors an aggregate of ~~830,308~~0.3 million shares of the Company’s Series C convertible preferred stock, par value $0.001 per share (the “Series C Shares”), at a weighted purchase price ~~between $15.25 and $16.00~~of $14.69 per share for ~~gross~~ proceeds of approximately ~~$12.9~~$4.8 million. ~~Pursuant to some of~~

During the ~~Series C Subscription Agreements, certain Series C investors chose to purchase~~six months ended June 30, 2023, the Company issued approximately 56,000 Series C Shares ~~by debt redemption. During the three months ended September 30, 2022, the Company extinguished approximately $2.0~~with a fair value of $1.0 million to certain lenders in lieu of cash payments of $0.9 million in debt, including $0.1 million of accrued ~~interest in lieu of partial consideration received for issuance~~interest. The Company recognized an approximately $0.1 million debt extinguishment loss.

During the six months ended June 30, 2023, approximately 0.3 million Series C ~~Shares. The Company received approximately $10.9~~Shares with a book value of $3.6 million net proceeds from issuance of the Series C Shares. Additionally, as a partial consideration for certain Series C investors, the Company agreed to amend the terms of the warrants that are currently held by them.

~~On August 12, 2022, an unrelated investor exercised existing warrants to purchase 1.4~~were converted into 6.4 million common shares at a weighted average exercise price of $0.24 per share and a total purchase price of approximately $329,000. The warrant holder agreed to receive Series C Preferred Shares instead of common shares, and agreed that these Series C shares could not be converted for a period of 3 months. Since Series C Preferred shares are convertible into common shares at a ratio of 1:125~~:25, the number of Series C Shares issued to the warrant holder was 1/25 of the 1.4 million common shares for which the warrants were exercisable, or 54,847 Series C Preferred Shares.~~

Each of the Series C Shares which were sold for prices between $15.25 and $16.00 per share will be convertible into 25 shares of common stock (equivalent to prices of $0.61 to $0.64 per share of common stock) at the option of the holder, but only after the convertibility date (between October 1, 2022 and December 28, 2022) as defined in the Series C Subscription Agreements..

The Company determined that the Series C Shares contain contingent redemption provisions allowing redemption by the holder upon certain defined events (“deemed liquidation events”). As the event that may trigger the redemption of the Series C Shares is not solely within the Company’s control, the Series C Shares are classified as mezzanine equity (temporary equity) in the Company’s condensed consolidated balance sheets.

~~10.~~11. Stockholders’ Deficit

Common Stock

~~Common Stock Issued for Cash~~

~~During~~On January 9, 2023, the ~~nine months ended September 30, 2022, t~~he Company ~~received $9.5 million from issuance~~filed a Certificate of ~~13.1 million~~Amendment of its Seventh Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of the State of Delaware, which effected an increase in the Company’s authorized shares of common stock, from 1.2 billion to ~~various investors.~~1.7 billion, par value $0.001 per share.

~~Warrants Exercised for Cash~~

During the ~~nine~~six months ended ~~September~~June 30, ~~2022,~~2023, the Company received ~~$10~~$2.8 million from the exercise of outstanding warrants ~~issued in the~~ ~~past~~ with an exercise price between ~~$0.18~~$0.153 and ~~$0.85.~~$0.85, of which $1.2 million was received in December 2022 as investor advances. The Company issued approximately ~~40.9~~12.3 million shares ~~of common stock and 0.3 million Series C convertible preferred stock in lieu~~ of common stock upon these warrant exercises.

~~Warrants and Options Cashless Exercise~~

During the ~~nine~~six months ended ~~September~~June 30, ~~2022,~~2023, certain ~~warrant~~options and warrants holders elected to exercise some of their options and warrants pursuant to cashless exercise formulas. The Company issued approximately 299.9 million shares of common stock ~~for~~upon exercise of ~~35.6~~10.6 million warrants ~~at exercise prices between $0.18~~ and ~~$0.52.~~

During the nine months ended September 30, 2022, certain options holders elected to exercise some of their options pursuant to cashless exercise formulas. The Company issued approximately 5.2 million shares of common stock for exercise of 8.21.5 million options at exercise prices between ~~$0.23~~$0.20 and ~~$0.34.~~$0.35.

1920

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

~~Debt Redemption~~

During the ~~nine~~six months ended ~~September~~June 30, ~~2022,~~ the Company issued approximately ~~10.4~~15.2 million shares of common stock to certain lenders in lieu of cash payments on $7$7.4 million of outstanding debt, including ~~$1.3~~$0.7 million ~~interest.~~interest, and settled $1.1 million true-up provision (see Note 7).

Stock Purchase Warrants

The following is a summary of warrant activity for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 (dollars in thousands, except per share data):

Number of

Weighted Average

Remaining

Number of

Weighted Average

Remaining

Warrants

Exercise Price

Contractual Term

Warrants

Exercise Price

Contractual Term

Outstanding as of January 1, 2022

225,469

0.30

0.96

Outstanding as of January 1, 2023

141,048

0.31

1.16

Warrants exercised for cash

(42,301)

0.24

(12,320)

0.22

—

Cashless warrrants exercise

(35,951)

0.23

(10,615)

0.20

—

Warrants expired and cancellation

(1,799)

1.58

(250)

1.36

—

Outstanding as of September 30, 2022

145,417

0.30

1.52

Outstanding as of June 30, 2023

117,863

0.31

1.72

The options and warrants held by Ms. Powers and Mr. Goldman are subject to an ongoing suspension on a rolling basis pursuant to the Blocker ~~Letter. In addition, other executive officers and directors extended their suspensions to various dates until at least November 30, 2022.~~Letter Agreement.

At ~~September~~June 30, ~~2022,~~2023, of the ~~145~~approximately 118 million total outstanding warrants listed above, approximately ~~142~~98 million warrants were under ~~block~~the Blocker Letter Agreement or suspension agreements.

~~At November 1, 2022, a total~~Warrant Modifications

Between January 10 and June 30, 2023, the Company amended multiple warrants whereby the maturity dates of ~~approximately 139 million~~certain warrants were ~~under block or suspension until between November 15, 2022~~extended for an additional approximately 3 months. The value of these modifications were calculated using the Black-Scholes-Merton option pricing model based on the following weighted average assumptions.


	Post-modification			Pre-modification
Exercise price	$	0.29		$	0.30
Expected term (in years)		1.9			1.6
Volatility		70	%		72	%
Risk-free interest rate		4.7	%		4.6	%
Dividend yield		0	%		0	%

The incremental fair value attributable to the modified awards compared to the original awards immediately prior to the modification was calculated at $1.1 million, of which $0.2 million was associated with debt financing and ~~January 15, 2023.~~was recognized as an additional debt discount (see Note 7), and the remaining $0.9 million was treated as a deemed dividend and is reflected as “Deemed dividend related to warrant modifications” in the accompanying condensed consolidated statement of operations and comprehensive loss.

~~11.~~12. Commitments and Contingencies

Operating Lease- Lessee Arrangements

The Company has operating leases for corporate offices in the U.S. and U.K., and for manufacturing facilities in the U.K. Leases with an initial term of 12 months or less are not recorded in the balance sheet. The Company has elected the practical expedient to account for each separate lease component of a contract and its associated non-lease components as a single lease component, thus causing all fixed payments to be capitalized. The Company also elected the package of practical expedients permitted within the new standard, which among other things, allows the Company to carry forward historical lease classification. The lease renewal options have not been included in the calculation of the lease liabilities and right-of-use (“ROU”) assets as the Company has not yet determined whether to exercise the options. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the ROU assets or liabilities. These are expensed as incurred and recorded as variable lease expense.

At September 30, 2022, the Company had operating lease liabilities of approximately $4.5 million for both the 20-year lease of the building for the manufacturing facility in Sawston, U.K., and the current office lease in the U.S. ROU assets of approximately $4.0 million for the Sawston lease and U.S. office lease are included in the condensed consolidated balance sheet.

2021

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

At June 30, 2023, the Company had operating lease liabilities of approximately $4.8 million for both the 20-year lease of the building for the manufacturing facility in Sawston, U.K., and the current office lease in the U.S. and ROU assets of approximately $4.2 million for the Sawston lease and U.S. office lease are included in the condensed consolidated balance sheet.

The following summarizes quantitative information about the Company’s operating leases (amount in thousands):


	For the Nine Months ended								For the six months ended
	September 30, 2022								June 30, 2023
	U.K			U.S			Total		U.K			U.S			Total
Lease cost
Operating lease cost	$	448		$	195		$	643	$	293		$	124		$	417
Short-term lease cost		56			—			56		49			—			49
Variable lease cost		—			9			9		—			7			7
Sub-lease income		(110)			—			(110)		(72)			—			(72)
Total	$	394		$	204		$	598	$	270		$	131		$	401

Other information
Operating cash flows from operating leases	$	(472)		$	(217)		$	(689)	$	(308)		$	(148)		$	(457)
Weighted-average remaining lease term – operating leases		8.6			1.4					8.2			0.9
Weighted-average discount rate – operating leases		12	%		12	%				12	%		12	%


	For the Nine Months Ended								For the Six Months ended
	September 30, 2021								June 30, 2022
	U.K			U.S			Total		U.K			U.S			Total
Lease cost
Operating lease cost	$	493		$	212		$	705	$	309		$	130		$	439
Short-term lease cost		38			—			38		34			—			34
Variable lease cost		48			5			53		—			12			12
Total	$	579		$	217		$	796		(73)			—			(73)
									$	270		$	142		$	412
Other information
Operating cash flows from operating leases	$	(519)		$	(84)		$	(603)	$	(325)		$	(144)		$	(469)
Weighted-average remaining lease term – operating leases		9.1			1.9					8.7			1.5
Weighted-average discount rate – operating leases		12	%		12	%				12	%		12	%

The Company recorded lease costs as a component of general and administrative expense during the ~~three and nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021,~~2022, respectively.

Maturities of our operating leases, excluding short-term leases and sublease agreement, are as follows:


Three months ended December 31, 2022	$	212
Year ended December 31, 2023		856
Six months ended December 31, 2023			$	466
Year ended December 31, 2024		762		838
Year ended December 31, 2025		557		633
Year ended December 31, 2026		557		633
Year ended December 31, 2027				633
Thereafter		6,663		6,947
Total		9,607		10,151
Less present value discount		(5,141)		(5,397)
Operating lease liabilities included in the Condensed Consolidated Balance Sheet at September 30, 2022	$	4,466
Operating lease liabilities included in the Condensed Consolidated Balance Sheet at June 30, 2023			$	4,754

2122

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

Maturities of our operating leases under the sublease agreement, ~~based on the current exchange rate,~~ are as follows:


Three months ended December 31, 2022	$	36
Year ended December 31, 2023		145
Six months ended December 31, 2023			$	73
Year ended December 31, 2024		145		145
Year ended December 31, 2025		145		145
Year ended December 31, 2026		145		145
Thereafter		1,740		1,740
Total	$	2,356	$	2,248

~~Manufacturing~~Advent BioServices Services ~~Agreements~~

~~Advent BioServices~~Agreement

On May 14, 2018, the Company entered into a DCVax®-L Manufacturing and Services Agreement (“MSA”) with Advent BioServices, a related party which was formerly part of Cognate BioServices and was spun off separately as part of an institutional financing of Cognate. The ~~Advent Agreement~~MSA provides for manufacturing of DCVax-L products at an existing facility in London. The ~~Agreement~~MSA is structured in the same manner as the Company’s prior agreements with Cognate BioServices. The ~~Advent Agreement~~MSA provides for certain payments for achievement of milestones and, as was the case under the prior agreement with Cognate BioServices, the Company is required to pay certain fees for dedicated production capacity reserved exclusively for DCVax production and pay for manufacturing of DCVax-L products for a certain minimum number of patients, whether or not the Company fully utilizes the dedicated capacity and number of patients. The MSA remains in force until five years after the first commercial sales of DCVax-L products pursuant to a marketing authorization, accelerated approval or other commercial approval, unless cancelled. Either party may terminate the MSA on twelve months’ notice, to allow for transition arrangements by both parties.

~~On November 8, 2019,~~ During the ~~Company and Advent entered into an Ancillary Services Agreement with an 8-month Term~~notice period services would still be provided. Minimum required payments for U.K. Facility Development Activities and Compassionate Use Program Activities. The Ancillary Services Agreement establishes a structure under which Advent develops Statements of Work (“SOWs”) for the U.K. Facility Development Activities and Compassionate Use Program Activities and delivers those SOWsthis notice period are anticipated to the Company for review and approval. After an SOW is approved by the Company, Advent will proceed with, or continue, the applicable services and will invoice the Company pursuant to the SOW. Since both the U.K. Facility Development and the Compassionate Use Program involve pioneering and uncertainties in most aspects, the invoicing under the Ancillary Services Agreement is on the basis of costs incurred plus fifteen percent. The Agreement also provides for Statements of Work (SOWs) with operational milestones and related payments. The Ancillary Services Agreement had an original term of eight months, which ended in July 2020. The Company extended the term by 12 months to July 2021 and another 12 months to July 2022, with no other changes, and recently extended it for another 12 months to July 2023.

The Company entered into SOW6 with Advent which was incorporated into the Ancillary Services Agreement on April 1, 2022 and amended on September 26, 2022. The amended SOW6 provides for six workstreams that are prerequisites for an application for regulatory approval of DCVax-L, for drafting of key portions of the application, and for three required licenses for the Sawston facility. The SOW provides for baseline costs and milestone incentives for completion of each of the workstreams, for the completion of the application for product approval, and for regulatory approval of each of the three Sawston licenses. The milestone incentives will be a combination of cash and stock and will not be paid until they are achieved and earned, as described in ~~Note 8. Related Parties Transactions above.~~total approximately £4.4 million ($5.6 million).

2223

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

The Company entered into SOW 6 with Advent, which was incorporated into the Ancillary Services Agreement on April 1, 2022 and amended it on September 26, 2022. The milestone incentives involve a combination of cash and stock and are not paid until they are achieved and earned, as described in Note9.

German Tax Matter

The German tax authorities have audited our wholly owned subsidiary, NW Bio GmbH, for ~~2013-2015. The~~2013-2015 and assessed additional tax against the subsidiary. NW Bio GmbH submitted substantial documentation to refute certain aspects of the assessments and the German tax authorities agreed in principle with the Company’s proposed revised approach and settlement offer. A final settlement bill was received from the German Tax Authority confirming that only a portion of the original bill was owed, €277,000 (approximately $329,000), for corporate taxes, interest, and reduced penalty for the period under audit, which the Company paid on September 2, 2021. The Company also received and paid the final settlement bill from the local authority for trade taxes for the audit period in the amount of €231,000 (approximately ~~$272,000)~~$251,000). On November 4, 2021, the Company received a letter from the local tax authorities asking for additional late fees of €513,000 (now approximately ~~$535,000)~~$558,000) on reimbursable withholding taxes that had been waived during the settlement process. On December 8, 2021, the Company appealed the assessment of additional late fees. Additionally, the Company requested that NW Bio GmbH be deregistered from the trade register, as it no longer had current operations. The deregistration was granted effective December 31, 2021. Between January 2022 and July 2022, the Company received tax bills for the corporate and trade taxes for the 2016-2020 tax years that totaled approximately €222,000 (approximately ~~$232,000)~~$241,000). On July 27, 2022, the Company was informed that the German Tax Authorities were prepared to waive €135,000 (approximately ~~$141,000)~~$147,000) of the penalties. The Company offered to pay this reduced penalty if an extended payment plan was ~~approved~~approved. A response was received dated November 14, 2022 indicating that the tax authority would not be able to grant a further deferral of payment of these penalties. In a letter dated December 27, 2022, the Leipzig tax authority sent letters to the former and ~~is awaiting~~current managing directors of NW Bio GmbH giving 30 days to respond to a ~~response.~~tax liability questionnaire. Based on the responses to the liability questionnaires the tax authorities have currently not directed any further measures against former and current managing directors of NW Bio GmbH with respect to tax liability proceedings. The Company currently has accrued for the current amounts owed for these penalties of €377,000 (approximately ~~$369,000) accrued~~$410,000) as well as for all unpaid taxes as of ~~September~~June 30, ~~2022.~~2023. Based on the Company’s current operating state in Germany and the negotiations, the Company believes, based on its evaluation under ASC 740, that the resolution of these tax matters will not likely result in a net material charge to the Company.

~~12. Subsequent Events~~

~~During the period from October 1, 2022 to November 7, 2022, the Company received an additional $2.0 million through equity subscriptions and warrant exercises.~~Other Contingent Payment Obligation

Between ~~October~~May and ~~November 2022,~~June 2023, the Company entered into ~~various Subscription Agreements (the “Series C Subscription Agreements”)~~certain non-dilutive funding agreements with ~~certain~~multiple investors, ~~(the “Series C Investors”). Pursuant~~pursuant to which the ~~Series C Subscription Agreements,~~Company received funding of $4.1 million related to a gain contingency. These agreements are accounted for under ASC 470 and are recognized as contingent payment obligations on the Company’s condensed consolidated balance sheet. The Company’s payment obligations only apply when such are received by the Company.

Table of Contents

NORTHWEST BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED STATEMENTS

13. Subsequent Events

Between July 1, 2023 and August 9, 2023, the Company received $2.1 million in funding from the sale of preferred shares and proceeds of debt arrangements and proceeds related to a gain contingency.

Between July 1, 2023 and August 9, 2023, the Company issued ~~to the~~approximately 84,000 shares of Series C Investors an aggregate of 98,535 shares of the Company’s Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Shares”), at a purchase price between $15.50 and $16.25 per sharepreferred stock for proceeds of $1.1 million.

In July 2023, approximately ~~$1.6 million. Each~~24,000 Series C ~~Preferred share is convertible to 25~~Shares with a book value of $0.4 million were converted into 0.6 million common shares in accordance with their terms at a ratio of 1:25.

Between July and August 2, 2023, the ~~option of the holder 3 months after the effective date of purchase.~~

~~During October 2022, 1.6~~Company issued approximately 4.9 million shares of common stock ~~were~~to a lender in lieu of cash payments on $2.5 million of outstanding debt, including $0.1 million interest. The Company also issued ~~upon warrant exercises for proceeds~~0.3 million shares of ~~approximately $0.4 million.~~common stock to that lender to extinguish $0.2 million Share liability.

~~Between October and November 2022,~~On July 11, 2023, the Company entered into ~~multiple~~a one-year convertible note ~~extension agreements for~~(the “July Convertible Note”) with an individual investor (the “Holder”) with an aggregate principal amount of ~~approximately $1.7~~$0.5 million. The Company received $0.5 million ~~whereby~~cash from the ~~maturity date~~July Convertible Note. The July Convertible Note bears interest at 10% per annum, and is convertible into Series C preferred shares at $12.50 per share at the Holder’s sole option. The Series C preferred shares are convertible into common stock 30 days after the debt conversion date. Each Series C preferred share is convertible into 25 shares of common stock.

Between July 1, 2023 and August 9, 2023, the ~~notes was extended for~~Company received $0.5 million in additional ~~3 months.~~non-dilutive funding related to a gain contingency.

2325

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements included with this report. In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “believe,” “expect,” “intend,” “anticipate,” and similar expressions are used to identify forward-looking statements, but some forward-looking statements are expressed differently. Many factors could affect our actual results, including those factors described under “Risk Factors” in our Form 10-K for the year ended December 31, ~~2021~~2022 and in Part II Item 1A of this report. These factors, among others, could cause results to differ materially from those presently anticipated by us. You should not place undue reliance on these forward-looking statements.

Overview

We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer.

Our lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for ~~Glioblastoma multiforme~~glioblastoma brain cancer ~~(GBM~~)(GBM). ~~On May 10, 2022, top line data from the Phase III~~

The trial results were presented inat a scientific conference in May 2022, and were reported in a peer reviewed publication in JAMA Oncology, a top scientific and medical journal.

In June 2023, the Company presented substantial information from analyses conducted by independent experts on the underlying biology and mechanism of action of its DCVax technology at an Industry Theater presentation during the ~~New York Academy~~ASCO (American Society of ~~Sciences~~Clinical Oncology) conference. The Company is pursuing further analyses by ~~one of the investigators in the trial. The presentation was made available publicly on a third-party site.~~independent experts, and plans to present further information at an appropriate future conference.

The Company is now ~~working on preparations~~in the final stages of preparing an application for ~~seeking~~ regulatory approval of DCVax-L.

~~Post-COVID difficulties continue to impact supply chains and program operations for~~ The Company is working with teams of specialized consultants on preparation of the ~~Company~~application package as well as related activities. One of the pre-requisites - obtaining regulatory approval of a Pediatric Investigation Plan (PIP) - was completed during 2022 on an accelerated basis, including regulatory approval to use the same trial design with external controls as was used in the Company’s Phase 3 trial.

In parallel with preparing the application for ~~other companies in this industry~~approval of DCVax-L, the Company is working with the contract research organization (CRO) and ~~others.~~ with specialized consultants on preparing the Trial Master File and sites to be inspection-ready for regulators.

The independent service firms have limited capacity, and still have some restrictions on operations. Key experts at certain specialized service providers have been unavailable for periods of time. Other experts have gone on extended leave. Clinical trial site personnel have been unavailable due to being reassigned for COVID,Company and the ~~limited site personnel have~~CRO continue to conduct long-term follow-up in connection with the Phase III trial of DCVax-L, as there are still patients alive.

The Company and Advent are working together to prepare for potential commercial operations. The buildout of Phase 1B of the Sawston facility, which had been under way since last year, has been completed. On July 24, 2023 the Company changed the name of its UK subsidiary from Aracaris Limited to Northwest Biotherapeutics Limited.

The Company’s wholly owned subsidiary, Flaskworks, is continuing its development work ~~under restrictions. Committee processes~~to optimize a system for closed and ~~regulatory processes that were focused on COVID matters during~~automated manufacturing of DCVax-L products, including optimizing yields. The Company views this as a centerpiece of efforts toward scale-up for potential commercial operations.

Supply chain issues and equipment backlogs continue to be factors affecting operations both for Advent and for Flaskworks. This includes months-long backlogs for certain equipment and materials. However, the ~~pandemic still have substantial backlogs and delays~~work is progressing in spite of the backlogs.

The Company is in active discussions in regard to ~~other matters. Service firms, vendors~~certain combination treatment regimens, and ~~suppliers also still have substantial backlogs and delays.~~is planning for certain strategic trials with such combination treatments.

~~On August 28, 2020,~~In the ~~Company acquired Flaskworks, LLC (“Flaskworks”), a company that has developed a system designed~~future, we plan to ~~close and automate the manufacturing~~conduct clinical trials of ~~cell therapy products such as DCVax®. The Company acquired 100%~~DCVax-L for other types of the ownership, and Flaskworks became a wholly-owned subsidiary of the Company. Flaskworks was previously owned by its technical founders and Corning Inc. The technical team from Flaskworks joined the Company as part of the Acquisition. It is anticipated that the Flaskworks system will enable substantial scale-up of production volumes of DCVax products and substantial reduction of production costs. Development work is ongoing. The Company’s buildout of the Sawston, UK facility has been designed to proceed in phases, as modules, both for efficiency in the timing of capital costs and to allow flexibility in operations and usage. The Company anticipates that implementation of the Flaskworks system will enable certain phases of the buildout to be simplified and streamlined.

solid tumor cancers, beyond brain cancer, when resources permit. Our second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed

Table of Contents

and it included treatment of a diverse range of more than a dozen types of cancers. ~~The Company plans~~We plan to work on preparations for Phase II trials of DCVax-Direct as resources permit.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect our reported amounts of assets, liabilities, revenues and expenses.

~~Table of Contents~~

On an ongoing basis, we evaluate our estimates and judgments, including those related to derivative liabilities, accrued expenses and stock-based compensation. We based our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ~~ongoing~~lingering effects from the coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.

Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. Our critical accounting policies and significant estimates have not changed substantially from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022 other than those included below.

Sequencing

The Company adopted a sequencing policy under ASC 815-40-35 to determine if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate if it has sufficient authorized shares. Certain contracts were classified as liabilities as the result of the instruments containing a potentially indeterminable number of shares and, most recently, due to the Company entering into agreements providing for the potential issuance of more shares than authorized. While temporary agreements are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the earliest grant date of potentially dilutive instruments. Pursuant to ASC 815, issuance of stock-based awards to the Company’s employees, nonemployees or directors are not subject to the sequencing policy.

Modification of Equity Classified Warrants

A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for any incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt financing, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend.

Results of Operations

Operating costs:

~~Operating~~Our operating costs and expenses consist primarily of research and development (R&D) expenses. R&D expenses ~~including~~include clinical trial expenses, ~~which increase when we are actively participating in clinical trials or we are undertaking substantial one-time expenses following trials, such as~~and increased costs after completion of a Phase III trial, especially for ~~statistical work under~~ the ~~Statistical Analysis Plan,~~extensive preparations, and ~~other activities related to completion and assessment~~teams of ~~the trial and its results, and to development of~~expert consultants, required for an application for ~~commercial approval~~product approval.

Table of ~~DCVax-L. The operating costs also include administrative expenses associated with trials, in addition to R&D expenses, and increase as such operating activities grow.~~Contents

In addition to clinical trial ~~related~~and post-trial costs, our operating costs may include ongoing work relating to our DCVax products, including R&D, product characterization, manufacturing process development, quality control process development, and related matters. ~~Going forward, we are also incurring large amounts~~Additional substantial costs relate to the development and expansion of ~~costs to carry out and complete statistical analyses, validation work, data reports and other work associated with analyzing the trial results and proceeding.~~

~~Following our acquisition of Flaskworks, our operating costs now include the costs for its ongoing operations and its intellectual property filings.~~manufacturing capacity.

Our operating costs also include ~~where applicable,~~ the costs of preparations for the launch of new or expanded clinical trial ~~programs.~~programs, such as our anticipated trials of combination treatment regimens. The preparation costs include payments to regulatory consultants, lawyers, statisticians, sites and others, evaluation of potential investigators, the clinical trial sites and the CROs managing the trials and other service providers, and expenses related to institutional approvals, clinical trial agreements (business contracts with sites), training of medical and other site personnel, trial supplies and other. ~~Additional substantial costs relate to the maintenance and substantial expansion of manufacturing capacity, in both the U.S. and Europe.~~

Our operating costs also include legal and accounting costs in operating the Company.

The foregoing operating costs include the costs for Flaskworks’ ongoing operations and intellectual property filings, and the operations of our subsidiaries in the U.K., the Netherlands and Germany.

Research and development:

~~Discovery and preclinical research and development~~R&D expenses include costs for substantial external scientific personnel, technical and regulatory advisers, and others, costs of laboratory supplies used in our internal research and development projects, travel, regulatory compliance, and expenditures for preclinical and clinical trial operation and management when we are actively engaged in clinical trials.

Because we are a pre-revenue company, we do not allocate ~~research and development~~R&D costs on a project basis. We adopted this policy, in part, due to the unreasonable cost burden associated with accounting at such a level of detail and our limited number of financial and personnel resources.

General and administrative:

General and administrative expenses include personnel related salary and benefit expenses, cost of facilities, insurance, travel, legal services, property and equipment and amortization of stock options and warrants.

Three Months Ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022

We recognized a net loss of ~~$32.9~~$14.4 million and ~~a net income of $45.5~~$29.7 million for the three months ended ~~September~~June 30, 2023 and 2022, respectively.

Research and ~~2021, respectively. The net income of $45.5 million for~~Development Expense

For the three months ended ~~September~~June 30, ~~2021 included a non-cash gain of $58.5~~2023 and 2022, research and development expense was $6.2 million ~~from change~~and $13.6 million, respectively. The decrease in ~~fair value derivative liabilities.~~2023 was mainly related to the following factors:

●

We incurred $0.1 million and $9.1 million R&D expense related to one-time milestone activities under the SOW 6 with Advent BioServices for the three months ended June 30, 2023 and 2022, respectively. We completed 9 out of the total 10 one-time milestones as of March 31, 2023, and therefore, we only expensed $0.1 million for the three months ended June 30, 2023 related to the remaining one milestone. During the three months ended June 30, 2022, we expensed $3.8 million (but only paid $0.5 million) for one-time cash milestones and $5.3 million (but only issued 1.5 million shares of common stock at fair value of $1.4 million) for one-time stock-based milestones that we believe are probable to be achieved and hence to become payable during the contract period.

●

The stock-based compensation in research and development related to stock options and Flaskworks performance-based awards were reduced by $0.5 million during the three months ended June 30, 2023 compared to the same period in 2022, which was related to less amortization related to previously granted awards.

●	An increased level of research and development activities in 2023 compared to 2022, which resulted in other R&D expenses increased by approximate $2.0 million.

2528

Table of Contents

~~Research~~General and ~~Development~~Administrative Expense

For the three months ended ~~September~~June 30, 2023 and 2022, general and ~~2021, research and development expense~~administrative expenses was ~~$7.7~~$7.6 million and ~~$3.7~~$7.9 million, respectively. The ~~increase~~decrease in 2023 was mainly related to ~~SOW6 that was entered into~~a decrease of $0.3 million in ~~April 2022~~consulting expense and ~~amended~~$0.4 million in ~~September 2022~~travel and conference expenses, which is partly offset by an increase of $0.2 million in stock-based compensation.

Change in Fair Value of Derivatives

We recognized a non-cash gain of $0.1 million and a non-cash loss of $4.3 million for six workstreams that are prerequisites for an application for regulatory approval of DCVax-L, for drafting of key portions of the application for commercial approval of DCVax-L, and for three required licenses for the Sawston facility. During the three months ended ~~September~~June 30, 2023 and 2022, ~~the Company incurred approximately $1.3 million expense related~~respectively. The non-cash gain in 2023 was primarily due to the baseline cost under the SOW6. In addition, during the three months ended September 30, 2022, for milestones that the Company believes are probable to be achieved in the future, the Company recognized the expense on pro-rata basis during the contract period: the Company expensed $1.5 million for cash milestones (but only paid $1.0 million) and $1.4 million for stock-based milestones.decrease of our stock price.

~~General and Administrative Expense~~

General and administrative expenses were $8.1 million and $6.7 million for three months ended September 30, 2022 and 2021, respectively. The increase was mainly related to an increase of $0.8 million stock-based compensation that represented the vesting of a portion of previously granted equity-based awards, and that was recognized in general and administrative expense.

~~Change in fair value of derivatives~~

~~During the three months ended September 30, 2022 and 2021, we recognized a non-cash loss of $12.2 million and a non-cash gain of $58.5 million, respectively.~~ The 2022 loss was primarily due to ~~an increase of stock price as of September 30, 2022 compared to June 30, 2022, and~~the extension of the exercise periods of certain ~~warrants. The 2021 gain was primarily due to the~~warrants and offset by a decrease of stock price as of ~~September~~June 30, ~~2021~~2022 compared to ~~June 30, 2021.~~March 31, 2022.

~~Loss from~~Debt Extinguishment ~~of Debt~~

During the three months ended ~~September~~June 30, ~~2022,~~2023, we issued approximately 6.9 million shares of common stock with a fair value of $3.9 million to certain lenders in lieu of cash payments of $3.2 million of debt, including $0.5 million accrued interest. In addition, pursuant to exchange agreements executed with various holders, the Company is required to potentially issue additional common stock (the “Share liability”) if the stock price is less than the price defined in the exchange agreement as of the true-up date. During the three months ended June 30, 2023, we extinguished Share liabilities of $0.4 million and recognized ~~a $0.5~~an additional $0.1 million of Share liabilities. We recognized an approximately $0.4 million debt extinguishment loss during the three months ended June 30, 2023 from the ~~redemption~~debt redemption.

During the three months ended June 30, 2023, we issued approximately 13,000 shares of Series C preferred stock at fair value of $0.2 million to certain ~~loans.~~lenders in lieu of cash payments of $0.2 million debt, including $25,000 accrued interest. We recognized an approximately $24,000 debt extinguishment loss.

Interest Expense

During the three months ended ~~September~~and June 30, 2023 and 2022, ~~and 2021, the Company recognized~~we recorded interest expense of ~~$1.5~~$1.3 million and ~~$1.6~~$1.4 million, respectively. The decrease in interest expense in 2023 was mainly related to a decrease of outstanding debt as a result of the redemption of approximate $18.1 million debt in 2022.

Foreign currency transaction ~~loss~~gain (loss)

During the three months ended and ~~September~~June 30, 2023 and 2022, ~~and 2021, the Company~~we recognized foreign currency transaction gain of $0.7 million and loss of ~~$3.1 million and $1.0~~$2.8 million, respectively. The gain during the three months ended June 30, 2023 was due to the weakening of the U.S. dollar relative to the British pound sterling, while the loss during the three months ended March 31, 2022 was due to the strengthening of the U.S. dollar relative to the British pound ~~sterling and Euro. The fluctuation of the exchange rates was larger in 2022 compared to the same period in 2021.~~sterling.

~~Nine~~Six Months Ended ~~September~~June 30, ~~2022~~2023 and ~~2021~~2022

~~The Company~~We recognized a net loss of ~~$76.7~~$25.1 million and ~~a net income of $45.8~~$43.9 million for the ~~nine~~six months ended ~~September~~June 30, 2023 and 2022, ~~and 2021,~~ respectively.

Research and Development Expense

For the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021,~~2022, research and development expense was ~~$26.2~~$13.1 million and ~~$16.1~~$18.5 million, respectively. The ~~increase of $10.1 million~~decrease in 2023 was mainly due to: (1) research and development costs under SOW6, including amounts expensed (but not paid) of $8.4 million for future milestones that are anticipated to be achieved and become payable in the future, and $3.6 million paid for milestones that have been achieved and awarded as outlined below; (2) a decrease of $5.2 million stock-based compensation, which was related to the ~~cancellation of certain unvested performance-based awards and less amortization related to previously granted awards.~~followings:

During the nine months ended September 30, 2022, the Company incurred approximately $2.6 million expense related to the baseline cost under the SOW6. In addition, during the nine months ended September 30, 2022, the Company expensed $5.3 million for cash

●

We incurred $1.4 million and $9.1 million R&D expense related to one-time milestone activities under the SOW 6 with Advent BioServices for the six months ended June 30, 2023 and 2022, respectively. Advent had completed 7 out of the total 10 one-time milestones as of December 31, 2022, and majority of the one-time R&D expense was recognized in 2022. Therefore, we only expensed $1.4 million for the six months ended June 30, 2023 related to the remaining 3 milestones. During the six months ended June 30, 2022, we expensed $3.8 million (but only paid $0.5 million) for one-time cash milestones and $5.3 million (but only issued

2629

Table of Contents

milestones (but only paid $1.5 million and accrued for $3.8 million) and $6.7 million (of which 2.5 million shares at fair value of $2.1 million were issued and accrued for $4.6 million) for stock-based milestones that the Company believes are probable to be achieved in the future and hence recognize the expense on pro-rata basis during the contract period.

1.5 million shares of common stock at fair value of $1.4 million) for one-time stock-based milestones that we believe are probable to be achieved and hence to become payable during the contract period.

●

The stock-based compensation in research and development related to stock options and Flaskworks performance-based awards were reduced by $0.8 million during the six months ended June 30, 2023 compared to the same period in 2022, which was related to less amortization related to previously granted awards.

●	An increased level of research and development activities in 2023 compared to 2022, which resulted in other R&D expenses increasing by approximately $3.0 million.

General and Administrative Expense

~~General~~For the six months ended June 30, 2023 and 2022, general and administrative expenses ~~were $23.9~~was $14.5 million and ~~$26.9~~$15.8 million, ~~for nine months ended September 30, 2022 and 2021,~~ respectively. The decrease in 2023 was mainly related to a decrease of ~~$6.5~~$1.2 million ~~stock-based compensation,~~in consulting expense and $0.4 million in travel and conference expenses, which ~~were related to the cancellation of certain unvested performance-based awards and less amortization related to previously granted awards and~~is offset by an increase of ~~approximately $2.9~~$0.1 million in ~~business travel costs, conferences expenses and D&O insurance premiums.~~stock-based compensation.

Change in ~~fair value~~Fair Value of ~~derivatives~~Derivatives

~~During the nine months ended September 30, 2022~~We recognized a non-cash gain of $4.0 million and ~~2021, we recognized~~ a non-cash loss of ~~$15.9~~$3.7 million for the six months ended June 30, 2023 and a2022, respectively. The non-cash gain in 2023 was primarily due to the decrease of ~~$93.5 million, respectively.~~ our stock price.

The 2022 loss was primarily due to the extension of the exercise periods of certain warrants and ~~an increase~~offset by a decrease of stock price as of ~~September~~June 30, 2022 compared to December 31, 2021. ~~The 2021 gain was primarily due~~

Debt Extinguishment

During the six months ended June 30, 2023, we issued approximately 15.2 million shares of common stock with a fair value of $9.6 million to certain lenders in lieu of cash payments of $7.4 million of debt, including $0.7 million accrued interest. In addition, pursuant to exchange agreements executed with various holders, the ~~decrease of~~Company is required to potentially issue additional common stock (the “Share liability”) if the stock price is less than the price defined in the exchange agreement as of ~~September 30, 2021 compared to December 31, 2020.~~

~~Gain (Loss) from Extinguishment of Debt~~

the true-up date. During the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023, we extinguished Share liabilities of $1.1 million and ~~2021, we~~ recognized an additional $0.6 million of Share liabilities. We recognized an approximately $1.8 million debt extinguishment loss during the six months ended June 30, 2023 from the debt redemption.

During the six months ended June 30, 2023, we issued approximately 56,000 shares of ~~$0.2~~Series C preferred stock at fair value of $1.0 million ~~and~~to certain lenders in lieu of cash payments of $0.9 million debt, including $0.1 million ~~respectively.~~accrued interest. We ~~incurred $0.4~~recognized an approximately $0.1 million ~~gain from the forgiveness of two PPP loans and offset by a loss of $0.6 million from redemption of certain loans during the nine months ended September 30, 2022.~~debt extinguishment loss.

Interest Expense

During the ~~nine~~six months ended ~~September~~and June 30, ~~2022~~2023 and ~~2021,~~2022, we recorded interest expense of ~~$4.8~~$2.3 million and ~~$3.9~~$3.3 million, respectively. The ~~increase~~decrease in interest expense in 2023 was ~~primarily due~~mainly related to ~~an increase~~a decrease of outstanding debt as a result of ~~December 31, 2021 compared to~~ the ~~outstanding balance as~~redemption of ~~December 31, 2020.~~approximate $18.1 million debt in 2022.

Foreign currency transaction ~~loss~~gain (loss)

During the ~~nine~~three months ended ~~September~~and June 30, ~~2022~~2023 and ~~2021,~~2022, we recognized foreign currency transaction gain of $1.6 million and loss of ~~$6.8 million and $1.4~~$3.7 million, respectively. The gain during the six months ended June 30, 2023 was due to the weakening of the U.S. dollar relative to the British pound sterling, while the loss during the six months ended June 30, 2022 was due to the strengthening of the U.S. dollar relative to the British pound ~~sterling and Euro, and the fluctuation was much higher this year compared to the same period of last year.~~sterling.

Liquidity and Capital Resources

We have experienced recurring losses from operations since inception. We have not yet established an ongoing source of revenues and must cover our operating expenses through debt and equity financings to allow us to continue as a going concern. Our ability to continue

Table of Contents

as a going concern depends on the ability to obtain adequate capital to fund operating losses until we generate adequate cash flows from operations to fund our operating costs and obligations. If we are unable to obtain adequate capital, we could be forced to cease operations.

We depend upon our ability, and will continue to attempt, to secure equity and/or debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. Our management determined that there was substantial doubt about our ability to continue as a going concern ~~within~~for at least one year after the ~~condensed~~annual consolidated financial statements were issued, and management’s concerns about our ability to continue as a going concern within the year following this report persist.

Cash Flow

Operating Activities

During the ~~nine~~six months ended ~~September~~June 30, ~~2022~~2023 and ~~2021,~~2022, net cash ~~used in~~outflows from operations were approximately ~~$43.9~~$22.8 million and ~~$27.1~~$27.8 million, respectively. The ~~increase~~decrease in cash used in operating activities was primarily attributable to ~~an increase~~a decrease of $4.2 million in ~~clinical trial related expenditures.~~

~~Table~~payments to external service providers and a decrease of ~~Contents~~$0.8 million interest payments to note holders.

Investing Activities

We spent approximately $2.6 million and $0.5 million in cash for the purchase of additional equipment and our build out in Sawston, UK during the six months ended June 30, 2023 and 2022, respectively.

Financing Activities

We received approximately ~~$11.0~~$4.8 million of cash from issuance of ~~0.9~~0.3 million shares of Series C convertible preferred stock during the ~~nine~~six months ended ~~September~~June 30, ~~2022.~~2023.

During the six months ended June 30, 2023, we received approximately $10.0 million in cash proceeds from the issuance of a loan to a commercial lender, and during the six months ended June 30, 2022, we received approximately $0.6 million in cash proceeds from the issuance of multiple loans to individual lenders.

We received approximately $1.6 million and $9.6 million of cash from the exercise of warrants during the three months ended June 30, 2023 and 2022, respectively.

We received approximately $9.5 million of cash from issuance of 13.1 million shares of common stock during the ~~nine~~six months ended ~~September~~June 30, 2022.

We received approximately ~~$10.0~~$1.1 million ~~and $12.1 million, in~~of cash from ~~the exercise~~issuance of ~~warrants and options~~convertible notes to individual lenders during the ~~nine~~six months ended ~~September~~June 30, ~~2022 and 2021, respectively.~~2023.

We received ~~approximately $5.6~~$4.1 million from ~~a loan from a commercial lender~~issuance of non-dilutive funding agreements during the ~~nine~~six months ended ~~September~~June 30, 2022. We received approximately $10.0 million cash proceeds from a loan from a commercial lender, $1.9 million cash from loans from various third-party lenders and $0.4 million from PPP loans during the nine months ended September 30, 2021.2023.

We made aggregate debt payments of ~~$5.4~~$0.2 million and ~~$2.0~~$5.3 million during the ~~nine~~six months ended ~~September~~June 30, 2023 and 2022, ~~and 2021,~~ respectively.

We made repayment of $0.1 million of investor advances during the six months ended June 30, 2023.

Other factors affecting our ongoing funding requirements include the number of staff we employ, the number of sites, number of patients and amount of activity in our clinical trial programs, the costs of further product and process development work relating to our DCVax products, the costs of preparations for Phase II trials, the costs of expansion of manufacturing, and unanticipated developments. The extent of resources available to us will determine which programs can move forward and at what pace.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risk represents the risk of loss that may result from the change in value of financial instruments due to fluctuations in its market price. Market risk is inherent in all financial instruments. Market risk may be exacerbated in times of trading illiquidity when market

Table of Contents

participants refrain from transacting in normal quantities and/or at normal bid-offer spreads. Our exposure to market risk is directly related to derivatives, debt and equity linked instruments related to our financing activities.

Our assets and liabilities are overwhelmingly denominated in U.S. dollars. We do not use foreign currency contracts or other derivative instruments to manage changes in currency rates. We do not now, nor do we plan to, use derivative financial instruments for speculative or trading purposes. However, these circumstances might change.

The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our interest rate risk exposure. For purposes of presenting the possible earnings effect of a hypothetical, adverse change in interest rates over the 12-month period from our reporting date, we assume that all interest rate sensitive financial instruments will be impacted by a hypothetical, immediate 100 basis point increase in interest rates as of the beginning of the period. The sensitivity is based upon the hypothetical assumption that all relevant types of interest rates that affect our results would increase instantaneously, simultaneously and to the same degree. We do not believe that our cash and equivalents have significant risk of default or illiquidity.

The sensitivity analyses of the interest rate sensitive financial instruments are hypothetical and should be used with caution. Changes in fair value based on a 1% or 2% variation in an estimate generally cannot be extrapolated because the relationship of the change in the estimate to the change in fair value may not be linear. Also, the effect of a variation in a particular estimate on the fair value of financial instruments is calculated independent of changes in any other estimate; in practice, changes in one factor may result in changes in another factor, which might magnify or counteract the sensitivities. In addition, the sensitivity analyses do not consider any action that we may take to mitigate the impact of any adverse changes in the key estimates.

Based on our analysis, as of ~~September~~June 30, ~~2022,~~2023, the effect of a 100+/- basis point change in interest rates on the value of our financial instruments and the resultant effect on our net loss are considered immaterial.

~~Table of Contents~~

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation as of ~~September~~June 30, ~~2022,~~2023, of the design and operation of our disclosure controls and procedures, as such terms are defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, management concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.

2932

Table of Contents

Part II - Other Information

Item 1. Legal Proceedings

~~Derivative Lawsuits by Putative Stockholders~~On December 1, 2022, we filed a Complaint in the United States District Court for the Southern District of New York against certain market makers. The Complaint alleges that the defendants engaged in manipulation of the Company’s stock, in violation of the Securities Exchange Act of 1934 and common law fraud, over a period of years. On March 20, 2023, the defendants filed a Motion to Dismiss the Complaint. On April 10, 2023, we filed an Amended Complaint against Canaccord Genuity LLC, Citadel Securities LLC, G1 Execution Services LLC, GTS Securities LLC, Instinet LLC, Lime Trading Corp., and Virtu Americas LLC (Northwest Biotherapeutics Inc. v. Canaccord, et al., No. 1:22-cv-10185-GHW-GWG). The Company plans to pursue this case vigorously.

~~In February and March,~~

As previously reported, three stockholders filed in the Delaware Court of Chancery three similar derivative lawsuits against the Company and certain of its directors and officers, including J. Cofer Black, Marnix L. Bosch, Alton L. Boynton, Leslie J. Goldman, Jerry Jasinowski, Navid Malik, and Linda F. Powers (the “Individual Defendants”), alleging the Individual Defendants (i) breached their fiduciary duties, and (ii) were unjustly enriched by director and officer compensation awarded to the Individual Defendants—notwithstanding the fact that approximately 90% of shareholders voted to approve of the Company’s executive compensation (the same compensation that these three stockholders are seeking to challenge) through its Say on Pay vote, and the director awards are subject to shareholder approval. On March 31, 2022, the Delaware Court of Chancery consolidated these actions into a single action under the caption In re Northwest Biotherapeutics, Inc. Stockholder Litigation (the “Derivative Action”).

The Company believes these cases are baseless and ~~intends to~~is vigorously ~~contest~~contesting the Derivative ~~Action.~~

Action.On December 30, 2022, shareholders approved the challenged grants to the directors and ratified the challenged awards to the officers. On February 22, 2023, the Company filed a Motion to Dismiss the case. The ~~Company~~parties fully briefed the motion in April 2023 and oral argument on the motion is ~~currently considering possibilities~~scheduled for ~~legal actions against third parties who have attacked the Company.~~September 2023.

Item 1A. Risk Factors

Applicable risk factors are set forth in the Company’s report on Form 10-K for ~~2021.~~2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

Not Applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

~~Not Applicable~~None.

3033

Table of Contents

Item 6. Exhibits


21.1		Subsidiaries of the Registrant

21.2		Certificate of Incorporation on Change of Name

31.1		Certification of President (Principal Executive Officer and Principal Financial and Accounting Officer), Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of President, Chief Executive Officer and Principal Financial and Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document.

101.SCH		Inline XBRL Schema Document.

101.CAL		Inline XBRL Calculation Linkbase Document.

101.DEF		Inline XBRL Definition Linkbase Document.

101.LAB		Inline XBRL Label Linkbase Document.

101.PRE		Inline XBRL Presentation Linkbase Document.

104		The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~September 30, 2022,~~March 31, 2023, formatted in Inline XBRL (included as Exhibit 101).

* Filed herewith

** Furnished herewith

3134

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NORTHWEST BIOTHERAPEUTICS, INC

Dated: ~~November~~August 9, ~~2022~~2023	By:	/s/ Linda F. Powers
		Name:	Linda F. Powers


		Title:	President and Chief Executive Officer

			Principal Executive Officer

			Principal Financial and Accounting Officer

3235


	September 30,		December 31,
	2022		2021
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	9,425	$	15,169
Prepaid expenses and other current assets		2,339		2,121
Total current assets		11,764		17,290

Non-current assets:
Property, plant and equipment, net		13,126		15,027
Right-of-use asset, net		3,951		4,889
Indefinite-lived intangible asset		1,292		1,292
Goodwill		626		626
Other assets		339		1,036
Total non-current assets		19,334		22,870

TOTAL ASSETS	$	31,098	$	40,160

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	8,237	$	6,976
Accounts payable and accrued expenses to related parties and affiliates		5,728		3,971
Convertible notes, net		135		135
Notes payable, net		20,032		7,104
Contingent payable derivative liability		8,012		8,232
Warrant liability		73,650		106,784
Lease liabilities		334		317
Shares payable		—		250
Total current liabilities		116,128		133,769

Non-current liabilities:
Notes payable, net of current portion, net		5,942		25,156
Lease liabilities, net of current portion		4,132		5,226
Total non-current liabilities		10,074		30,382

Total liabilities		126,202		164,151

COMMITMENTS AND CONTINGENCIES (Note 11)

MEZZANINE EQUITY
Series C Convertible Preferred Stock, 10,000,000 shares designated; 885,155 and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively; aggregate liquidation preference of $13.2 million		13,746		—

Stockholders’ deficit:
Preferred stock ($0.001 par value); 100,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively		—		—
Common stock ($0.001 par value); 1,200,000,000 shares authorized; 1,051.3 million and 948.4 million shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		1,051		948
Additional paid-in capital		1,152,689		1,066,873
Stock subscription receivable		(79)		(79)
Accumulated deficit		(1,268,824)		(1,192,090)
Accumulated other comprehensive income		6,313		357
Total stockholders’ deficit		(108,850)		(123,991)

TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT	$	31,098	$	40,160


	As of September 30, 2022
	Warrant			Contingent Payable
	Liability			Derivative Liability
Strike price	$	0.30		$	0.71	*
Contractual term (years)		1.5			0.6
Volatility (annual)		69	%		82	%
Risk-free rate		3.8	%		3.9	%
Dividend yield (per share)		0	%		0	%


	As of December 31, 2021
	Warrant			Contingent Payable
	Liability			Derivative Liability
Strike price	$	0.30		$	0.70	*
Contractual term (years)		1.0			1.6
Volatility (annual)		90	%		72	%
Risk-free rate		0.1	%		0.6	%
Dividend yield (per share)		0	%		0	%


	For the nine months
	ended
	September 30, 2022
Exercise price	$	0.65
Expected term (years)		3.9
Expected stock price volatility		99	%
Risk-free rate		3.3	%
Dividend yield (per share)		0	%